1343 genotypes with 1843 annotations displayed
of selected term and subterms
|
Searched Term: autoimmune response
|
1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/0
(NOD.FVB-1700016L21RikTg(Itgax-HBEGF/EGFP)57Lan/Jdk)
|
decreased susceptibility to autoimmune diabetes
|
J:137009
|
AA467197em1Nyam/AA467197em1Nyam
(C.B6-AA467197em1Nyam)
|
increased susceptibility to autoimmune disorder
|
J:347271
|
Abattm1c(EUCOMM)Hmgu/Abattm1c(EUCOMM)Hmgu Tg(Cd4-cre)1Cwi/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
Acantm2Afos/Acantm2Afos
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:122102
|
Ackr4tm1.1Rjbn/Ackr4tm1.1Rjbn
(B6.129S6-Ackr4tm1.1Rjbn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:166490
|
Acla1BXSB/Slc/Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla1NZW/Slc/Acla1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla2BXSB/Slc/Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Acla2NZW/Slc/Acla2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Actbtm4(cre/ERT2)Npa/Actb+ Sgpl1tm1.1Npa/Sgpl1tm1.1Npa
(involves: BALB/cJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199525
|
Adam8tm1.1Mdz/Adam8tm1.1Mdz
(DBA/1LacJ-Adam8tm1.1Mdz)
|
decreased susceptibility to induced arthritis
|
J:155243
|
Adamts5tm1.1Eam/Adamts5+
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
Adamts5tm1.1Eam/Adamts5tm1.1Eam
(involves: 129S5/SvEvBrd)
|
decreased susceptibility to induced arthritis
|
J:97590
|
Adamts5tm2.2Lex/Adamts5tm2.2Lex
(B6.129S5-Adamts5tm2.2Lex)
|
decreased susceptibility to induced arthritis
|
J:175366
|
Adaz1NZM2328/J/Adaz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased anti-double stranded DNA antibody level
|
J:71397
|
Adgrd1tm1b(EUCOMM)Wtsi/Adgrd1tm1b(EUCOMM)Wtsi
(C57BL/6N-Adgrd1tm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Ads1NZB/Ads1NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7239,
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads1NZB/Ads1NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads2NZB/Ads2NZB
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads2NZB/Ads2NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7111
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads3NZB/Ads3NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads3NZW/Ads3NZW
(involves: NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:7239
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads4NZB/Ads4NZB
(involves: NZB * NZW)
|
decreased anti-double stranded DNA antibody level
|
J:11074
|
Ads4NZB/Ads4NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Ads4NZW/Ads4NZW
(involves: NZB * NZW)
|
increased susceptibility to autoimmune disorder
|
J:7111
|
Aec1NOD/Uf/Aec1NOD/Uf Aec2NOD/Uf/Aec2NOD/Uf
(B6.NOD-Aec2NOD/Uf Aec1NOD/Uf)
|
increased anti-nuclear antigen antibody level
|
J:129282
|
increased susceptibility to autoimmune disorder
|
J:128900
|
Aem1C57BL/6/Aem1NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:7191
|
Aem2C57BL/6/Aem2C57BL/6
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Aem2C57BL/6/Aem2NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Aem2C57BL/6/Aem2NZB Aem3C57BL/6/Aem3NZB
(involves: C57BL/6 * NZB)
|
decreased autoantibody level
|
J:59427
|
Agnm1MRL/MpJ/Agnm1MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm2C3H/HeJ/Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm2MRL/MpJ/Agnm2MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm3C3H/HeJ/Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Agnm3MRL/MpJ/Agnm3MRL/MpJ
(involves: C3H/HeJ-Faslpr * MRL/MpJ-Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:97786
|
Aia1NZB/Omr/Aia1NZB/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
Aia1NZB/Omr/Aia1NZC/Omr
(involves: NZB/Omr * NZC/Omr)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:6517
|
Aif1tm1Nsib/Aif1tm1Nsib
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:204462
|
Aim2tm1.2Arte/Aim2tm1.2Arte Dnase2atm1Osa/Dnase2atm1Osa Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129 * BALB/c * C57BL/6 * C57BL/6J)
|
increased autoantibody level
|
J:238323
|
rheumatoid arthritis
|
J:238323
|
Airetm1.1Doi/Airetm1.1Doi
(involves: 129S2/SvPas * C57BL/6)
|
increased autoantibody level
|
J:119475
|
increased susceptibility to autoimmune disorder
|
J:83422
|
Airetm1.1Doi/Airetm1.1Doi
(B6.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(NOD.129S2(B6)-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(C.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
Airetm1.1Doi/Airetm1.1Doi
(SJL.129S2-Airetm1.1Doi/Doi)
|
increased autoantibody level
|
J:107432
|
Airetm1Mand/Aire+
(NOD.129P2-Airetm1Mand)
|
increased autoantibody level
|
J:188686
|
increased susceptibility to autoimmune diabetes
|
J:135154,
J:188686
|
Airetm1Mmat/Airetm1Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:96580
|
Airetm1Mmat/Airetm1Mmat
(C.Cg-Airetm1Mmat)
|
increased autoantibody level
|
J:96580
|
Airetm1Mmat/Airetm1Mmat
(B6.Cg-Airetm1Mmat)
|
autoimmune response
|
J:96580
|
Airetm1Mmat/Airetm2Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:141379
|
Airetm1Pltn/Airetm1Pltn
(involves: 129S4/SvJae * C57BL/6)
|
increased autoantibody level
|
J:77873
|
Airetm1Ptsn/Airetm1Ptsn
(C57BL/6-Airetm1Ptsn)
|
increased autoantibody level
|
J:145910
|
Airetm1Ptsn/Airetm1Ptsn
(C.B6-Airetm1Ptsn)
|
increased susceptibility to autoimmune disorder
|
J:174653
|
Airetm2Mmat/Airetm2Mmat
(involves: C57BL/6 * CBA)
|
autoimmune response
|
J:141379
|
Alox5tm1Fun/Alox5tm1Fun
(B6.129S2-Alox5tm1Fun/J)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:108446
|
Alox5aptm1Jdm/Alox5ap+
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased susceptibility to induced arthritis
|
J:100736
|
Alox5aptm1Jdm/Alox5aptm1Jdm
(DBA/1LacJ-Alox5aptm1Jdm)
|
decreased susceptibility to induced arthritis
|
J:100736
|
anan/anan
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
anan/anan+
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
anaya/anaya
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
andra/andra
(involves: C57BL/6 * C57BL/10Sg * C57BR/c)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
Anta/Anta+
(involves: C57BL/6 * C57BL/10 * C57BR/cd)
|
increased anti-nuclear antigen antibody level
|
J:169366
|
Apcstm1Mpe/Apcs+
(B6.Cg-Apcstm1Mpe)
|
increased autoantibody level
|
J:90502
|
Apcstm1Mpe/Apcstm1Mpe
(B6.Cg-Apcstm1Mpe)
|
increased autoantibody level
|
J:90502
|
Apcstm1Smae/Apcstm1Smae
(involves: 129S/SvEv * C57BL/6)
|
increased autoantibody level
|
J:71194
|
Apoetm1Unc/Apoetm1Unc
(B6.129P2-Apoetm1Unc/J)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc
(B6.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc Faslpr/Faslpr
(MRL.Cg-Apoetm1Unc Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:133606
|
increased anti-nuclear antigen antibody level
|
J:133606
|
increased autoantibody level
|
J:133606
|
increased susceptibility to systemic lupus erythematosus
|
J:133606
|
Apoetm1Unc/Apoetm1Unc Faslpr/Faslpr
(B6.Cg-Apoetm1Unc Faslpr)
|
decreased autoantibody level
|
J:121671
|
increased anti-double stranded DNA antibody level
|
J:121671
|
increased autoantibody level
|
J:121671
|
Apoetm1Unc/Apoetm1Unc Faslgld/Faslgld
(B6.Cg-Faslgld Apoetm1Unc)
|
increased anti-nuclear antigen antibody level
|
J:200141,
J:91058
|
increased autoantibody level
|
J:91058
|
Arid5atm1Rnis/Arid5atm1Rnis
(B6.Cg-Arid5atm1Rnis)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:197418
|
Arigg1NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg2NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg3NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg4NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg5NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg6NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg7NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg8BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg9NZB/BlNJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Arigg10BALB/cByJ/?
(involves: BALB/cByJ * NZB/BlNJ)
|
increased anti-erythrocyte antigen antibody level
|
J:93737
|
Art2atm1Fkn/Art2atm1Fkn Art2btm1Fkn/Art2btm1Fkn Cd38tm1Lnd/Cd38tm1Lnd
(NOD.129(B6)-Cd38tm1Lnd Art2atm1Fkn Art2btm1Fkn/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:108097
|
asa/asa
(either: A/J or BALB/c or DBA/2J)
|
increased autoantibody level
|
J:2843
|
Asbb1BALB/c/Asbb1BALB/c
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb2BALB/c/Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb2C57BL/6J/Asbb2C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Asbb3C57BL/6J/Asbb3C57BL/6J
(involves: BALB/c * C57BL/6J)
|
increased susceptibility to systemic lupus erythematosus
|
J:76486
|
Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu
(B6.FVB-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu)
|
increased autoantibody level
|
J:208213
|
increased susceptibility to autoimmune disorder
|
J:208213
|
increased susceptibility to induced arthritis
|
J:208213
|
Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu/Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf/Il6tm1Kopf
(B6.Cg-Ash1lTn(pb-Act-RFP)1.AF0-180T25Zhu Il6tm1Kopf)
|
increased susceptibility to induced arthritis
|
J:208213
|
Atg5tm1Myok/Atg5tm1Myok Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Atg7tm1Tchi/Atg7tm1Tchi Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * C57BL/6NCrlj * CBA/JNCrlj)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Atxn3tm1a(KOMP)Wtsi/Atxn3tm1a(KOMP)Wtsi
(C57BL/6N-Atxn3tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Aviltm2(cre)Fawa/Aviltm2(cre)Fawa
(B6J.129P2-Aviltm2(cre)Fawa)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:265529
|
Axltm1Grl/Axltm1Grl Mertktm1Grl/Mertktm1Grl
(involves: C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
Axltm1Grl/Axltm1Grl Mertktm1Grl/Mertktm1Grl Tyro3tm1Grl/Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
abnormal susceptibility to autoimmune disorder
|
J:70420
|
increased anti-double stranded DNA antibody level
|
J:70420
|
increased autoantibody level
|
J:70420
|
Axltm1Grl/Axltm1Grl Tyro3tm1Grl/Tyro3tm1Grl
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:70420
|
B2mtm1Unc/B2mtm1Unc
(NOD.129P2-B2mtm1Unc)
|
decreased susceptibility to autoimmune diabetes
|
J:121685,
J:17000
|
B2mtm1Unc/B2mtm1Unc
(B6.129P2-B2mtm1Unc/DcrJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
B2mtm1Unc/B2mtm1Unc Ciitatm1Ccum/Ciitatm1Ccum
(NOD.Cg-B2mtm1Unc Ciitatm1Ccum)
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
B2mtm1Unc/B2mtm1Unc Emv30b/Emv30b Prkdcscid/Prkdcscid Tg(B2M)55Hpl/? Mcph1Tg(HLA-A2.1)1Enge/?
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Emv30b Prkdcscid Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
B2mtm1Unc/B2mtm1Unc Tg(B2M)55Hpl/0
(NOD.Cg-B2mtm1Unc Tg(B2M)55Hpl/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:71837
|
B2mtm1Unc/B2mtm1Unc Tg(B2M)55Hpl/Tg(B2M)55Hpl Mcph1Tg(HLA-A2.1)1Enge/Mcph1Tg(HLA-A2.1)1Enge
(NOD.Cg-B2mtm1Unc Mcph1Tg(HLA-A2.1)1Enge Tg(B2M)55Hpl)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
B2mtm1Unc/B2mtm1Unc Tg(GFAP-B2m)9Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
B2mtm1Unc/B2mtm1Unc Tg(GFAP-B2m)#Mdos/?
(involves: 129P2/OlaHsd * C57BL/6 * NOD/ShiLtJ)
|
decreased susceptibility to autoimmune diabetes
|
J:135214
|
B2mtm1Unc/B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
B2mtm1Unc/B2mtm1Unc Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-B2mtm1Unc Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
B2mtm1Unc/B2mtm1Unc X/Yaa
(BXSB.129P2(B6)-B2mtm1Unc/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123547
|
increased anti-double stranded DNA antibody level
|
J:123547
|
increased anti-nuclear antigen antibody level
|
J:123547
|
B9d2/Tgfb1tm1Flv/Tgfb1tm2Flv Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
B9d2/Tgfb1tm1Flv/B9d2+ Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:169839
|
Bak1tm1Thsn/Bak1tm1Thsn Baxtm1Sjk/Baxtm2Sjk Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased anti-double stranded DNA antibody level
|
J:100463
|
increased susceptibility to autoimmune disorder
|
J:100463
|
Batftm1.1Kmm/Batftm1.1Kmm
(129S6/SvEvTac-Batftm1.1Kmm)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150643
|
Bcl2l1tm1Cant/Bcl2l1tm1Cant
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:77507
|
Bcl2l11tm1.1Ast/Bcl2l11+
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:58641
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
(involves: 129S1/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to autoimmune disorder
|
J:58641
|
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Faslpr/Faslpr
(B6.Cg-Bcl2l11tm1.1Ast Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
increased susceptibility to autoimmune disorder
|
J:132217
|
Becn1tm1.1Bflu/Becn1tm1.1Bflu Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203090
|
Becn1tm1Ebr/Becn1tm1Ebr Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Bhlhe40tm1Tan/Bhlhe40tm1Tan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
abnormal susceptibility to autoimmune disorder
|
J:72651
|
increased anti-nuclear antigen antibody level
|
J:72651
|
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:94297
|
Bmxtm1Ali/Bmxtm1Ali
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to induced arthritis
|
J:173099
|
Bsgtm1Tmu/Bsgtm1Tmu
(involves: 129S2/SvPas)
|
increased susceptibility to systemic lupus erythematosus
|
J:287636
|
Btkxid/? Ptpn6me/Ptpn6me
(involves: C57BL/6J * CBA/N * NFS)
|
increased autoantibody level
|
J:30994
|
Btkxid/Btkxid
(CBA/CaHN-Btkxid/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92639
|
Btkxid/Btkxid
(CBA/HN-Btkxid)
|
autoimmune response
|
J:125114
|
Btlatm1Kmm/Btlatm1Kmm
(involves: 129S/SvEv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84084
|
Btn2a2tm1.2Wrth/Btn2a2tm1.2Wrth
(C57BL/6-Btn2a2tm1.2Wrth)
|
increased anti-nuclear antigen antibody level
|
J:232636
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:232636
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
increased autoantibody level
|
J:145903
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ
(B10.BXSB-(D13Mit3-D13Mit78))
|
autoimmune response
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ Gpab1C57BL/6J/?
(involves: BXSB/MpJ * C57BL/10ScSnOlaHsd)
|
autoimmune response
|
J:145903
|
increased autoantibody level
|
J:145903
|
Bxs6BXSB/MpJ/Bxs6BXSB/MpJ X/Yaa
(B10.BXSB-(D13Mit3-D13Mit78) Yaa)
|
autoimmune response
|
J:145049
|
increased anti-double stranded DNA antibody level
|
J:145049
|
increased anti-single stranded DNA antibody level
|
J:145049
|
increased autoantibody level
|
J:145049
|
C1qatm1Mjw/C1qatm1Mjw
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-histone antibody level
|
J:47315
|
increased anti-nuclear antigen antibody level
|
J:47315
|
C1qatm1Mjw/C1qatm1Mjw Sle16129S6/SvEvTac/Sle16129S6/SvEvTac
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle16129S6/SvEvTac/Sle16C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle18C57BL/6/Sle18C57BL/6
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle18C57BL/6/Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle19C57BL/6/?
(involves: 129S/SvEv * 129X1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle19C57BL/6/?
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/? Sle18C57BL/6/Sle18C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/Sle21129P2/Ola
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qatm1Mjw/C1qatm1Mjw Sle21129P2/Ola/Sle21C57BL/6
(involves: 129P2/Ola * 129S/SvEv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:118645
|
increased anti-double stranded DNA antibody level
|
J:118645
|
increased anti-nuclear antigen antibody level
|
J:118645
|
increased anti-single stranded DNA antibody level
|
J:118645
|
increased susceptibility to systemic lupus erythematosus
|
J:118645
|
C1qtnf3tm1Yiw/C1qtnf3tm1Yiw
(involves: C57BL/6NSlc)
|
increased susceptibility to induced arthritis
|
J:211893
|
C1qtnf6tm1Yiw/C1qtnf6tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:227217
|
increased autoantibody level
|
J:227217
|
C1qtnf6tm1Yiw/C1qtnf6tm1Yiw
(B6.129P2-C1qtnf6tm1Yiw)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:227217
|
increased susceptibility to induced arthritis
|
J:227217
|
C3tm1Crr/C3tm1Crr
(B6.129S4-C3tm1Crr)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
C3tm1Crr/C3tm1Crr C4btm1Crr/C4btm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
C3tm1Crr/C3tm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
decreased susceptibility to autoimmune disorder
|
J:127292
|
C3tm1Crr/C3tm1Crr Fcer1gtm1Rav/Fcer1gtm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
C3tm1Crr/C3tm1Crr Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
C3tm1Pkna/C3tm1Pkna
(D1.129P2-C3tm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
C3ar1tm1Raw/C3ar1tm1Raw
(B6.129X1(B6)-C3ar1tm1Raw)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:93791
|
C4btm1Crr/C4btm1Crr
(involves: 129S4/SvJae * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:111811
|
increased anti-nuclear antigen antibody level
|
J:111811
|
increased anti-single stranded DNA antibody level
|
J:111811
|
C4btm1Crr/C4btm1Crr Faslpr/Faslpr
(involves: 129S4/SvJae * C57BL/6 * MRL)
|
increased anti-double stranded DNA antibody level
|
J:127292
|
increased anti-nuclear antigen antibody level
|
J:127292
|
C9orf72em1Eggn/C9orf72em1Eggn
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
C9orf72tm1.1Eggn/C9orf72+
(involves: C57BL/6 * C57BL/6N)
|
increased autoantibody level
|
J:240357
|
C9orf72tm1.1Eggn/C9orf72tm1.1Eggn
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased autoantibody level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
C9orf72tm1Eggn/C9orf72tm1Eggn
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:240357
|
increased susceptibility to autoimmune disorder
|
J:240357
|
Card19tm1Rwen/Card19tm1Rwen
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased autoantibody level
|
J:336763
|
Casp1tm1Flv/Casp1tm1Flv Casp4del/Casp4del
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57101
|
Cblbtm1Hua/Cblbtm1Hua
(B6.129P2-Cblbtm1Hua)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
Cblbtm1Hua/Cblbtm1Hua Ubash3btm1Jni/Ubash3btm1Jni Ubash3atm1Jni/Ubash3atm1Jni
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
Ccl2tm1Rol/Ccl2tm1Rol
(B6.129S4-Ccl2tm1Rol)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
Ccl2tm1Rol/Ccl2tm1Rol
(SJL.129S4-Ccl2tm1Rol)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:68145
|
Ccl4em1Narl/Ccl4em1Narl
(C57BL/6JNarl-Ccl4em1Narl)
|
decreased susceptibility to autoimmune diabetes
|
J:346348
|
Ccnt1Gt(RRR115)Byg/Ccnt1Gt(RRR115)Byg
(involves: 129P2/OlaHsd)
|
autoimmune response
|
J:130071
|
Ccr1tm1Cge/Ccr1tm1Cge
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:63952
|
Ccr2tm1Ifc/Ccr2tm1Ifc
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:75838
|
Ccr2tm2.1Ifc/Ccr2tm2.1Ifc Cx3cr1tm1Litt/Cx3cr1+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
Ccr2tm2.1Ifc/Ccr2tm2.1Ifc Cx3cr1tm1Litt/Cx3cr1tm1Litt
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:166664
|
Ccr6tm1Lira/Ccr6tm1Lira
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148286
|
Ccr7tm1Rfor/Ccr7tm1Rfor
(B6.129P2-Ccr7tm1Rfor)
|
increased susceptibility to autoimmune disorder
|
J:110910
|
Ccr8tm1Lira/Ccr8tm1Lira
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
Cd1d1tm1Crw/Cd1d1tm1Crw
(B6.129S4-Cd1d1tm1Crw)
|
decreased susceptibility to induced arthritis
|
J:99107
|
Cd1d1tm1Luc/Cd1d1tm1Luc
(B6.129S6-Cd1d1tm1Luc)
|
autoimmune response
|
J:122245
|
Cd1d1tm1Luc/Cd1d1tm1Luc
(C.129S6-Cd1d1tm1Luc)
|
increased anti-double stranded DNA antibody level
|
J:121187
|
increased anti-nuclear antigen antibody level
|
J:121187
|
Cd1d1tm1Luc/Cd1d1tm1Luc Cx3cr1tm1Litt/Cx3cr1tm1Litt
(B6.129-Cd1d1tm1Luc Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cd4tm1(cre/ERT2)Thbu/Cd4+ Gfm1tm1c(EUCOMM)Wtsi/Gfm1tm1c(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:302272
|
Cd4tm1Knw/Cd4tm1Knw
(NOD.Cg-Cd4tm1Knw)
|
decreased susceptibility to autoimmune diabetes
|
J:93553
|
Cd4tm1Knw/Cd4tm1Knw Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Cd4tm1Knw Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Cd4tm1Mak/Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.Cg-Cd4tm1Mak Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Cd5tm1.1Chra/Cd5tm1.1Chra
(involves: C57BL/6 * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
Cd5tm1Cgn/Cd5tm1Cgn
(B6.129P2-Cd5tm1Cgn)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189919
|
Cd8atm1Mak/Cd8atm1Mak Il15tm1Imx/Il15tm1Imx X/Yaa
(BXSB.Cg-Cd8atm1Mak Il15tm1Imx/Dcr)
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Cd8atm1Mak/Cd8atm1Mak X/Yaa
(BXSB.129S2(B6)-Cd8atm1Mak/4Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Cd19tm1(cre)Cgn/Cd19+ Ep300tm2Reck/Ep300+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:147840
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
Cd19tm1(cre)Cgn/Cd19+ Ep300tm2Reck/Ep300+
(involves: 129/Sv * 129P2/OlaHsd * FVB/N)
|
increased susceptibility to systemic lupus erythematosus
|
J:147840
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Ach/Fastm1Ach
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Cd19tm1(cre)Cgn/Cd19+ Fastm1Cgn/Fastm1Cgn
(B6.Cg-Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(Cd74/MOG)Awai/Gt(ROSA)26Sor+ Il10tm1Roer/Il10tm1Roer
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Cd19tm1(cre)Cgn/Cd19+ Ptpn6tm1Rsky/Ptpn6tm1Rsky
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:123568
|
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm1.1Awai/Tnfaip3tm1.1Awai
(involves: 129P2/OlaHsd)
|
increased anti-nuclear antigen antibody level
|
J:175422
|
Cd19tm1(cre)Cgn/Cd19+ Tnfaip3tm2Ama/Tnfaip3+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased autoantibody level
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
Cd19tm1Tft/Cd19tm1Tft
(B6.Cg-Cd19tm1Tft)
|
decreased anti-double stranded DNA antibody level
|
J:136210
|
decreased anti-nuclear antigen antibody level
|
J:136210
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:106487
|
Cd19tm1Tft/Cd19tm1Tft Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased anti-double stranded DNA antibody level
|
J:71174
|
decreased susceptibility to systemic lupus erythematosus
|
J:71174
|
Cd22tm1Msn/Cd22tm1Msn
(either: (involves: 129S/SvEv * BALB/c) or (involves: 129S/SvEv * C57BL/6J))
|
increased anti-double stranded DNA antibody level
|
J:76974,
J:76975
|
Cd22tm2Lnit/Cd22tm2Lnit
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:198790
|
Cd22tm3Lnit/Cd22tm3Lnit
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
autoimmune response
|
J:198790
|
Cd28tm1Jmg/Cd28tm1Jmg
(B6.129X1-Cd28tm1Jmg)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
Cd28tm1Ltu/Cd28tm1Ltu Foxp3tm4(YFP/icre)Ayr/Foxp3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:194503
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:194503
|
Cd28tm1Mak/Cd28tm1Mak
(NOD.129S2-Cd28tm1Mak)
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
Cd28tm1Mak/Cd28tm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149888
|
Cd28tm1Mak/Cd28tm1Mak
(B6.129S2-Cd28tm1Mak/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
Cd28tm1Mak/Cd28tm1Mak Cd40lgtm1Flv/Cd40lgtm1Flv
(NOD.Cg-Cd40lgtm1Flv Cd28tm1Mak)
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
Cd28tm1Shr/Cd28tm1Shr Ctla4tm1Shr/Ctla4+
(C.129S4-Cd28tm1Shr Ctla4tm1Shr)
|
increased susceptibility to autoimmune disorder
|
J:125259
|
Cd38tm1Lnd/Cd38tm1Lnd
(NOD.129P2(B6)-Cd38tm1Lnd/LtJ)
|
increased susceptibility to autoimmune diabetes
|
J:108097
|
Cd40tm1Kik/Cd40tm1Kik Tg(Tnfsf13b)1Fma/?
(B6.Cg-Cd40tm1Kik Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Cd40lgtm1Flv/Y Faslpr/Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
Cd40lgtm1Flv/Y Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
Cd40lgtm1Flv/Cd40lgtm1Flv
(NOD.129S2-Cd40lgtm1Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:93421
|
Cd40lgtm1Flv/Cd40lgtm1Flv Faslpr/Faslpr
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
Cd40lgtm1Flv/Cd40lgtm1Flv Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
increased anti-double stranded DNA antibody level
|
J:38492
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu
(B6.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
Cd44tm1.1Ugu/Cd44tm1.1Ugu
(SJL.129(Cg)-Cd44tm1.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
Cd44tm1Mak/Cd44tm1Mak
(D1.129P2-Cd44tm1Mak)
|
increased susceptibility to induced arthritis
|
J:95275
|
Cd44tm2.1Ugu/Cd44tm2.1Ugu
(B6.129-Cd44tm2.1Ugu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:199279
|
Cd44tm2Kmz/Cd44tm2Kmz
(DBA/1LacJ-Cd44tm2Kmz)
|
decreased susceptibility to induced arthritis
|
J:74268
|
Cd55tm1Mme/Cd55tm1Mme
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:80116
|
Cd55tm1Song/Cd55tm1Song
(B6.129S6-Cd55tm1Song)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
Cd55tm1Song/Cd55tm1Song Cd59atm1Bpm/Cd59atm1Bpm
(B6.129-Cd55tm1Song Cd59atm1Bpm)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
Cd59atm1Bpm/Cd59atm1Bpm
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89014
|
Cd59atm1Bpm/Cd59atm1Bpm
(involves: 129)
|
increased susceptibility to induced arthritis
|
J:146711
|
Cd59atm1Bpm/Cd59atm1Bpm
(B6.129-Cd59atm1Bpm)
|
increased susceptibility to experimental autoimmune myasthenia gravis
|
J:113567
|
Cd69tm1Naka/Cd69tm1Naka
(C.129P2-Cd69tm1Naka)
|
decreased susceptibility to induced arthritis
|
J:84940
|
Cd72b/Cd72b Faslpr/Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
decreased anti-double stranded DNA antibody level
|
J:204782
|
decreased anti-nuclear antigen antibody level
|
J:204782
|
decreased susceptibility to autoimmune disorder
|
J:204782
|
Cd72c/Cd72c Faslpr/Faslpr
(involves: C57BL/6 * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
increased susceptibility to systemic lupus erythematosus
|
J:204782
|
Cd72tm1Tsub/Cd72tm1Tsub
(involves: C57BL/6J)
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
Cd72tm1Tsub/Cd72tm1Tsub Faslpr/Faslpr
(involves: C57BL/6J * C57BL/6JJmsSlc * MRL/Mp)
|
autoimmune response
|
J:204782
|
increased anti-chromatin antibody level
|
J:204782
|
increased anti-double stranded DNA antibody level
|
J:204782
|
increased anti-single stranded DNA antibody level
|
J:204782
|
Cd74tm1Liz/Cd74tm1Liz
(involves: 129S/SvEv * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
Cd74tm1Liz/Cd74tm1Liz
(B6.129S-Cd74tm1Liz)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
Cd74tm2Liz/Cd74tm2Liz
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
Cd74tm3Liz/Cd74tm3Liz
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
Cd79atm1(cre)Reth/Cd79a+ Inpp5dtm1Rav/Inpp5dtm1Rav
(involves: 129 * BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:178833
|
increased anti-double stranded DNA antibody level
|
J:178833
|
increased anti-nuclear antigen antibody level
|
J:178833
|
increased anti-single stranded DNA antibody level
|
J:178833
|
increased autoantibody level
|
J:178833
|
increased susceptibility to systemic lupus erythematosus
|
J:178833
|
Cd79atm1(cre)Reth/Cd79a+ Wastm1.1Ldn/Y
(involves: BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
Cd79atm1(cre)Reth/Cd79a+ Wastm1.1Ldn/Wastm1.1Ldn
(involves: BALB/c * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
Cd79atm1.1Rsky/Cd79atm1.1Rsky
(involves: C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:179254
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm1Shr/Cd86tm1Shr
(B6.129S4-Cd80tm1Shr Cd86tm1Shr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:57613
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae)
|
increased susceptibility to autoimmune diabetes
|
J:113109
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:61905
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(129.SJL-Cd86tm2Shr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:78992
|
Cd80tm1Shr/Cd80tm1Shr Cd86tm2Shr/Cd86tm2Shr Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(involves: 129S4/SvJae * FVB/N * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
Cd86tm1Shr/Cd86tm1Shr
(NOD.129S4-Cd86tm1Shr)
|
decreased susceptibility to autoimmune diabetes
|
J:71352
|
increased autoantibody level
|
J:142046
|
increased susceptibility to autoimmune diabetes
|
J:93421
|
Cd180tm1Kmiy/Cd180tm1Kmiy Faslpr/Faslpr
(MRL.Cg-Cd180tm1Kmiy Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
Cd200tm1Jods/Cd200tm1Jods
(C57BL/6-Cd200tm1Jods)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:65982
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:79906
|
increased susceptibility to induced arthritis
|
J:65982
|
Cd247tm2.1Lov/Cd247tm2.1Lov
(B6.Cg-Cd247tm2.1Lov)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:192915
|
Cd274tm1.1Lex/Cd274tm1.1Lex
(involves: 129S5/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
Cd274tm1Lpc/Cd274tm1Lpc
(B6.129S-Cd274tm1Lpc)
|
increased susceptibility to autoimmune disorder
|
J:89781
|
Cd274tm1Lpc/Cd274tm1Lpc
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142815
|
Cd274tm1Lpc/Cd274tm1Lpc
(C.129S-Cd274tm1Lpc)
|
increased susceptibility to induced arthritis
|
J:165841
|
Cd274tm1Shr/Cd274tm1Shr
(C.B6-Cd274tm1Shr)
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
Cd274tm1Shr/Cd274tm1Shr Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
Cd276tm1Lpc/Cd276tm1Lpc
(B6.129-Cd276tm1Lpc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:237700
|
Cd276tm1Lpc/Cd276tm1Lpc
(D1J.129-Cd276tm1Lpc)
|
decreased susceptibility to induced arthritis
|
J:237700
|
Cd276tm1Mak/Cd276tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:84973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:84973
|
Cd300lftm1Gne/Cd300lftm1Gne
(involves: C57BL/6N)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:156819
|
Cdk2tm2Sgo/Cdk2tm2Sgo Cdk4tm2.1Bbd/Cdk4tm2.1Bbd Polr2atm1(cre/ERT2)Bbd/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:125217
|
Cdk4tm1Kiyo/Cdk4+ Lin9tm1Orc/Lin9+
(involves: 129S1/Sv)
|
decreased susceptibility to autoimmune diabetes
|
J:111333
|
Cdkn1atm1Led/Cdkn1atm1Led
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
Cdkn1atm1Led/Cdkn1atm1Led Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6))
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(B6;129S2-Cdkn1atm1Tyj/J)
|
decreased susceptibility to induced arthritis
|
J:108569
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:60292
|
increased anti-histone antibody level
|
J:60292
|
increased anti-nuclear antigen antibody level
|
J:60292
|
Ceat1CBA/J/Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
Ceat1NOD/Ceat1NOD
(involves: CBA/J * NOD-H2k)
|
increased susceptibility to experimental autoimmune thyroiditis
|
J:77545
|
Cfbtm1Pkna/Cfbtm1Pkna
(D1.129P2-Cfbtm1Pkna)
|
decreased susceptibility to induced arthritis
|
J:88872
|
Cfptm1Song/Cfptm1Song
(involves: 129 * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:165497
|
Cfptm2.1Song/Cfptm2.1Song Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * SJL)
|
decreased susceptibility to induced arthritis
|
J:165497
|
Cgnz1NZM2328/J/Cgnz1NZM2328/J
(involves: C57L/J * NZM2328/J)
|
increased susceptibility to systemic lupus erythematosus
|
J:71397
|
Chuktm2Mka/Chuktm2Mka Tg(Tnfsf13b)1Fma/?
(B6.Cg-Chuktm2Mka Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Cia2DBA/1J/Cia2DBA/1J
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:116665
|
Cia5bRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia5bRIIIS/J/Cia5bRIIIS/J Cia32B10.RIII/Cia32RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia5cRIIIS/J/?
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia7DBA/1J/Cia7DBA/1J
(involves: B10.Q * DBA/1)
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia30RIIIS/J/Cia30RIIIS/J Cia5B10.RIII/Cia5B10.RIII
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
Cia31B10.RIII/Cia31RIIIS/J Cia5RIIIS/J/Cia5RIIIS/J
(involves: C57BL/10 * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:101767
|
Cia34DBA/1J/Cia34DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35C57BL/10SnSg Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia35C57BL/10SnSg/Cia35DBA/1J Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia35DBA/1J/Cia35DBA/1J Cia42DBA/1J/Cia42DBA/1J
(involves: B10.Q * DBA/1)
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia36DBA/1J/Cia36DBA/1J
(involves: C57BL/10 * DBA/1J)
|
decreased autoantibody level
|
J:122130
|
decreased susceptibility to induced arthritis
|
J:122130
|
Cia37C57BL/10SnSg/Cia37DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia38DBA/1J/Cia38DBA/1J
(involves: C57BL/10 * DBA/1J)
|
increased autoantibody level
|
J:122130
|
increased susceptibility to induced arthritis
|
J:122130
|
Cia39C57BL/10Sn/Cia39C57BL/10Sn
(involves: B10.Q/Lund-H2q * B10.RIII/Lund-H2r)
|
decreased susceptibility to induced arthritis
|
J:97801
|
Cia40C57BL/10SnSg/Cia40C57BL/10SnSg
(involves: C57BL/10SnSg * DBA/1J * NFS/N)
|
increased susceptibility to induced arthritis
|
J:106522
|
Cia43DBA/1J/Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
Cia43FVB/N/Cia43FVB/N
(involves: DBA/1J * FVB/N)
|
increased susceptibility to induced arthritis
|
J:146242
|
Ciaaq1DBA/1J/Ciaaq1DBA/1J
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
Ciaaq1DBA/1J/Ciaaq1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased autoantibody level
|
J:122919
|
Ciitatm1Ccum/Ciitatm1Ccum
(NOD.129S2(B6)-Ciitatm1Ccum)
|
decreased susceptibility to autoimmune diabetes
|
J:107051
|
Ciitatm1Jpyt/Ciitatm1Jpyt
(B6.129P2-Ciitatm1Jpyt)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
Clec1atm1Yiw/Clec1atm1Yiw
(involves: C57BL/6J * C57BL/6NSlc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:329240
|
Clec4a2tm1Yiw/Clec4a2tm1Yiw
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:217720
|
increased autoantibody level
|
J:217720
|
increased susceptibility to induced arthritis
|
J:217720
|
Clec4dtm1.1Shoy/Clec4dtm1.1Shoy
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
Clec4etm1Tks/Clec4etm1Tks
(involves: 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:203159
|
Clec5atm1Cua/Clec5atm1Cua
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:158811
|
Cntftm1Mpin/Cntftm1Mpin
(B6.129S2-Cntftm1Mpin)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126852
|
Cog6tm1a(EUCOMM)Wtsi/Cog6tm1a(EUCOMM)Wtsi
(C57BL/6N-Cog6tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Col17a1tm1Shzu/Col17a1tm1Shzu Tg(KRT14-COL17A1)1Shzu/0
(involves: 129S/SvEv * C57BL/6J * C57BL/6Ncr)
|
decreased autoantibody level
|
J:121695
|
Col17a1tm1Tiin/Col17a1tm1Tiin
(involves: C57BL/6)
|
increased autoantibody level
|
J:220622
|
Coro1aLmb3-C57BL/6Scr/Coro1aLmb3-C57BL/6Scr
(MRL.Cg-Coro1aC57BL/6Scr Faslpr)
|
decreased autoantibody level
|
J:125557
|
decreased susceptibility to systemic lupus erythematosus
|
J:125557
|
Coro1aLmb3-MRL/MpScr/Coro1aLmb3-MRL/MpScr
(B6.MRL-Coro1aMRL/MpScr Faslpr)
|
increased susceptibility to systemic lupus erythematosus
|
J:125557
|
Cr2tm1Crr/Cr2tm1Crr
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:111811
|
Crhtm1Maj/Crhtm1Maj
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98419
|
Cry1tm1Jhjh/Cry1tm1Jhjh Cry2tm1Jhjh/Cry2tm1Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:159504
|
Csf2tm1Dran/Csf2tm1Dran Il3tm1Glli/Il3tm1Glli
(B6.129S2-Csf2tm1Dran Il3tm1Glli)
|
increased anti-double stranded DNA antibody level
|
J:83086
|
Csf2tm1Mlg/Csf2tm1Mlg
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148120
|
Csf3tm1Ard/Csf3tm1Ard Junbtm3Wag/Junbtm3Wag Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
Ctla4tm1Saka/Ctla4tm1Saka Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
increased autoantibody level
|
J:140085
|
Ctla4tm1Shr/Ctla4tm1Shr
(B6.129S4-Ctla4tm1Shr)
|
autoimmune response
|
J:146644
|
Ctsbtm1Jde/Ctsb+
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
Ctsbtm1Jde/Ctsbtm1Jde
(NOD.129P2-Ctsbtm1Jde)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
Ctsltm1Cptr/Ctsl+
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
Ctsltm1Cptr/Ctsltm1Cptr
(NOD.129P2-Ctsltm1Cptr)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
Ctsstm1Eae/Ctsstm1Eae
(involves: C57BL/6 * DBA/1LacJ)
|
decreased susceptibility to induced arthritis
|
J:53399
|
Ctsstm1Eae/Ctsstm1Eae
(NOD.D1-Ctsstm1Eae)
|
decreased susceptibility to autoimmune diabetes
|
J:153355
|
Ctsstm1Hap/Ctsstm1Hap
(B6.129S2-Ctsstm1Hap)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:96401
|
Cx3cr1tm1Litt/Cx3cr1+
(B6.129P2-Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cx3cr1tm1Litt/Cx3cr1tm1Litt
(B6.129P2-Cx3cr1tm1Litt)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:129712
|
Cxcl10tm1Adl/Cxcl10tm1Adl
(B6.129S4-Cxcl10tm1Adl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87076
|
Cxcr2tm1a(EUCOMM)Wtsi/Cxcr2tm1a(EUCOMM)Wtsi
(C57BL/6N-Cxcr2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Cxcr2tm1Mwm/Cxcr2tm1Mwm
(C.129S2(B6)-Cxcr2tm1Mwm/J)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Cxcr4tm1Yiw/Cxcr4tm1Yiw Tg(Lck-cre)1Jtak/0
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:164872
|
Cybbtm1Din/Cybbtm1Din
(B6.129S-Cybbtm1Din/J)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Cyp19a1tm1Esi/Cyp19a1tm1Esi
(involves: 129S6/SvEvTac * C57BL/6)
|
increased autoantibody level
|
J:92438
|
Cyp19a1tm1Sih/Cyp19a1tm1Sih
(involves: 129S/SvEv)
|
increased anti-single stranded DNA antibody level
|
J:216958
|
increased autoantibody level
|
J:216958
|
increased susceptibility to autoimmune disorder
|
J:216958
|
Cysltr2tm1Ykn/Cysltr2tm1Ykn
(C.B6-Cysltr2tm1Ykn)
|
autoimmune response
|
J:182213
|
Cytl1tm1Chun/Cytl1tm1Chun
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:175377
|
DbaclC57BL/6Jcl/DbaclC57BL/6Jcl
(NOD.B6-(D4Mit193-D4Mit17))
|
increased susceptibility to autoimmune diabetes
|
J:144964
|
Dcbld2tm1a(KOMP)Wtsi/Dcbld2tm1a(KOMP)Wtsi
(C57BL/6N-Dcbld2tm1a(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dclk1tm1a(EUCOMM)Wtsi/Dclk1+
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dclk1tm1a(EUCOMM)Wtsi/Dclk1tm1a(EUCOMM)Wtsi
(C57BL/6N-Dclk1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Def6Gt(OST307148)Lex/Def6Gt(OST307148)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:106469
|
Del(1Aim2-Ifi205)1Stsn/+ Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
Del(1Aim2-Ifi205)1Stsn/Del(1Aim2-Ifi205)1Stsn Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
Del(3Cd1d2-Cd1d1)1Crw/Del(3Cd1d2-Cd1d1)1Crw Tg(TcraAV19AJ33)1Shima/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
Del(14Ltb4r2-Ltb4r1)1Bodd/+
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
Del(14Ltb4r2-Ltb4r1)1Bodd/Del(14Ltb4r2-Ltb4r1)1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:131779
|
Dffbem1(IMPC)Wtsi/Dffbem1(IMPC)Wtsi
(C57BL/6N-Dffbem1(IMPC)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Dgkztm1Gak/Dgkztm1Gak
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:293120
|
Dh/Dh+ H2d/H2d
(NZB.Cg-Dh)
|
increased anti-erythrocyte antigen antibody level
|
J:12036
|
increased anti-nuclear antigen antibody level
|
J:12036
|
increased anti-single stranded DNA antibody level
|
J:12036
|
increased autoantibody level
|
J:12036
|
Dicer1tm1Tara/Dicer1tm1Tara Foxn1tm3(cre)Nrm/Foxn1+
(involves: 129P2/OlaHsd * C57BL/6NHsd)
|
increased susceptibility to induced arthritis
|
J:180783
|
Dnase1tm1Tmo/Dnase1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:62549
|
Dnase1tm1Tmo/Dnase1tm1Tmo
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:62549
|
increased susceptibility to systemic lupus erythematosus
|
J:62549
|
Dnase1tm1Tmo/Dnase1tm1Tmo
(involves: 129P2/OlaHsd * CD-1)
|
decreased susceptibility to systemic lupus erythematosus
|
J:110060
|
Dnase1tm2092.1Arte/Dnase1tm2092.1Arte
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:277126
|
increased anti-histone antibody level
|
J:277126
|
increased anti-nuclear antigen antibody level
|
J:277126
|
increased autoantibody level
|
J:277126
|
increased susceptibility to systemic lupus erythematosus
|
J:277126
|
Dnase2atm1Osa/Dnase2atm1Osa Ifnar1tm1Agt/Ifnar1tm1Agt
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:114982
|
increased autoantibody level
|
J:238323
|
rheumatoid arthritis
|
J:238323,
J:114982
|
Dnase2atm1Osa/Dnase2atm2Osa Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA)
|
rheumatoid arthritis
|
J:114982
|
Dntttm1Gfn/Dntttm1Gfn Faslpr/Faslpr
(involves: 129S2/SvPas * C57BL/6 * MRL/MpJ)
|
decreased autoantibody level
|
J:110248
|
Dock2m1Hsd/Dock2m1Hsd Siaetm1.2Avrk/Siaetm1.2Avrk
(B6NHsd.Cg-Siaetm1.2Avrk Dock2m1Hsd)
|
increased anti-double stranded DNA antibody level
|
J:144035
|
increased anti-histone antibody level
|
J:144035
|
increased anti-single stranded DNA antibody level
|
J:144035
|
Dock8pri/Dock8pri
(involves: C57BL/6JAnu)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Dock10tm1Thar/Dock10tm1Thar
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:300632
|
Dtx1tm1.1Mzl/Dtx1tm1.1Mzl Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
increased autoantibody level
|
J:151605
|
Dtx1tm1.2Mzl/Dtx1tm1.2Mzl
(B6.129-Dtx1tm1.2Mzl)
|
increased anti-double stranded DNA antibody level
|
J:151605
|
increased anti-histone antibody level
|
J:151605
|
Dusp1tm1Lex/Dusp1tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:126383
|
Dusp2tm1Cmac/Dusp2tm1Cmac
(B6.Cg-Dusp2tm1Cmac)
|
decreased susceptibility to induced arthritis
|
J:112609
|
Dusp10tm1Flv/Dusp10tm1Flv
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92104
|
Dusp14Gt(OST210117)Lex/Dusp14Gt(OST210117)Lex
(B6.129S5-Dusp14Gt(OST210117)Lex)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209403
|
Dusp22tm1Tht/Dusp22tm1Tht
(B6.129S7-Dusp22tm1Tht)
|
increased susceptibility to autoimmune disorder
|
J:213253
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:213253
|
E2f1tm1Meg/E2f1tm1Meg
(NOD.Cg-E2f1tm1Meg)
|
increased susceptibility to autoimmune diabetes
|
J:93708
|
E2f2tm1Zubi/E2f2tm1Zubi
(involves: 129S1/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:76318
|
increased susceptibility to autoimmune disorder
|
J:76318
|
E2f2tm1Zubi/E2f2tm1Zubi Tg(TcraH-Y,TcrbH-Y)71Vbo/?
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2J)
|
increased susceptibility to autoimmune disorder
|
J:76318
|
Eae1A/J/Eae1A/J
(involves: A/J * C57BL/10SnJ)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
Eae1PL/J/Eae1PL/J
(involves: C57BL/10SnJ * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:30574
|
Eae2RIIIS/J/Eae2RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
decreased susceptibility to induced arthritis
|
J:95848
|
Eae4ABH/?
(involves: ABH * NOD)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
Eae5B10.S/DvTe/Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae5SJL/J/Eae5SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7B10.S/DvTe/Eae7B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7B10.S/DvTe/Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae7SJL/J/Eae7SJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae9B10.S/DvTe/Eae9SJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae10SJL/J/Eae10SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae11SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae12SJL/J/Eae12SJL/J
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae13SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae14C57BL/10/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
Eae17SJL/J/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:69083
|
Eae18NOD/Eae18NOD
(involves: ABH * NOD)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:29171
|
Eae26B10.RIII/Eae26B10.RIII
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
Eae26B10.RIII/Eae26RIIIS/J
(involves: B10.RIII * RIIIS/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:73850
|
Eae33C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae34C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae35C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:99793
|
Eae36SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae37C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae38C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
increased susceptibility to autoimmune disorder
|
J:99793
|
Eae42C57BL/10SnSg/?
(involves: B10.S * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Eae42SJL/J/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Eae43B10.S/DvTe/?
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:53193
|
Eae43B10.S/DvTe/Eae43B10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Eae44aB10.S/DvTe/Eae44aB10.S/DvTe
(involves: B10.S/DvTe * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Eae44bB10.S/DvTe/Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Eae44bSJL/J/Eae44bSJL/J
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:56752
|
Ecm1tm1Bsun/Ecm1tm1Bsun
(involves: 129 * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:168252
|
Edil3Tg(lacZ)1Tq/Edil3Tg(lacZ)1Tq
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:254384
|
Elavl1tm1.1Atas/Elavl1tm1.1Atas Tnfrsf4tm2(cre)Nik/Tnfrsf4+
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:207013
|
Endoutm1Tft/Endoutm1Tft Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129S/SvEv * C57BL/6 * C57BL/6JSfd)
|
increased autoantibody level
|
J:208364
|
Entpd7tm1Ktak/Entpd7tm1Ktak
(B6.Cg-Entpd7tm1Ktak)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:191188
|
Ephb6tm1Jwu/Ephb6tm1Jwu
(involves: 129)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94701
|
Erars1DBA/2J/?
(involves: BXD2/TyJ * C57BL/6J * DBA/2J)
|
increased anti-nuclear antigen antibody level
|
J:96064
|
Ergtm1.1Iwamo/Ergtm1.1Iwamo Tg(Gdf5-cre,-ALPP)1Kng/?
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased susceptibility to induced arthritis
|
J:243715
|
Esr1tm1Ksk/Esr1tm1Ksk
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:88156
|
Extl1em1Caox/Extl1em1Caox Tg(Itgax-cre)1-1Reiz/0
(involves: C57BL/6 * CBA)
|
increased susceptibility to autoimmune disorder
|
J:333437
|
F2tm2Jld/F2+
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2J)
|
decreased susceptibility to induced arthritis
|
J:174629
|
F2rl1tm1Wrf/F2rl1tm1Wrf
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:81119
|
Faddtm1Mpa/Faddtm1Mpa Mogtm1(cre)Gkl/Mog+
(involves: C57BL/6 * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:167475
|
Fam210bem1Cya/Fam210bem1Cya
(involves: C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:351618
|
increased anti-nuclear antigen antibody level
|
J:351618
|
Faslpr-cg/Faslpr-cg
(CBA/KlJms-Faslpr-cg/J)
|
autoimmune response
|
J:24805,
J:81770
|
increased anti-nuclear antigen antibody level
|
J:24805
|
increased autoantibody level
|
J:81770
|
Faslpr/Faslpr
(MRL/Mp-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:27634,
J:131138,
J:6257
|
increased anti-erythrocyte antigen antibody level
|
J:27634
|
increased anti-nuclear antigen antibody level
|
J:27634,
J:28885
|
increased anti-single stranded DNA antibody level
|
J:27634
|
increased autoantibody level
|
J:28885
|
increased susceptibility to autoimmune disorder
|
J:108760
|
Faslpr/Faslpr
(NOD.MRL(B6)-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Faslpr/Faslpr
(MRL/MpJ-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:92084,
J:122315,
J:7454
|
increased anti-nuclear antigen antibody level
|
J:111811,
J:92084,
J:14151,
J:7454
|
increased autoantibody level
|
J:92084,
J:14151
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
Faslpr/Faslpr
(NOD.MRL-Faslpr)
|
decreased susceptibility to autoimmune diabetes
|
J:78679
|
Faslpr/Faslpr
(involves: C3H * MRL/Mp)
|
autoimmune response
|
J:1060
|
increased anti-nuclear antigen antibody level
|
J:34296
|
increased susceptibility to systemic lupus erythematosus
|
J:34296
|
Faslpr/Faslpr
(B6.MRL-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:132217
|
increased anti-histone antibody level
|
J:132217
|
increased anti-nuclear antigen antibody level
|
J:132217
|
increased anti-single stranded DNA antibody level
|
J:132217
|
increased autoantibody level
|
J:132217
|
Faslpr/Faslpr
(MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:126261
|
increased anti-nuclear antigen antibody level
|
J:126261
|
Faslpr/Faslpr
(MRL.Cg-Irf1tm1Mak Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:114771
|
Faslpr/Faslpr
(C3.MRL-Faslpr/J)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
Faslpr/Faslpr
(B6.MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:6638,
J:135036
|
increased autoantibody level
|
J:135036,
J:7454
|
Faslpr/Faslpr
(AK.MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:7454
|
increased anti-nuclear antigen antibody level
|
J:7454
|
increased autoantibody level
|
J:7454
|
Faslpr/Faslpr
(MRL/MpJ-Faslpr)
|
autoimmune response
|
J:125114
|
increased anti-nuclear antigen antibody level
|
J:137066
|
increased autoantibody level
|
J:137066
|
Faslpr/Faslpr
(involves: C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
Faslpr/Faslpr Fcer1gtm1Tks/Fcer1gtm1Tks
(MRL.Cg-Fcer1gtm1Tks Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:106188
|
Faslpr/Faslpr Havcr1tm1Kuch/Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:186484
|
increased autoantibody level
|
J:186484
|
increased susceptibility to systemic lupus erythematosus
|
J:186484
|
Faslpr/Faslpr Hspa13tm1.1Smoc/Hspa13tm1.1Smoc Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6 * MRL/Mp)
|
decreased autoantibody level
|
J:303927
|
decreased susceptibility to systemic lupus erythematosus
|
J:303927
|
Faslpr/Faslpr Ifnar1tm1Agt/Ifnar1tm1Agt
(MRL.Cg-Ifnar1tm1Agt Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:92084
|
increased autoantibody level
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
Faslpr/Faslpr Ifnar1tm1Agt/Ifnar1tm1Agt Ifngr1tm1Agt/Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Ifnar1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
increased susceptibility to systemic lupus erythematosus
|
J:92084
|
Faslpr/Faslpr Ifngtm1Ts/Ifng+
(MRL.Cg-Ifngtm1Ts Faslpr)
|
increased autoantibody level
|
J:123834
|
Faslpr/Faslpr Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
Faslpr/Faslpr Ifngr1tm1Agt/Ifngr1tm1Agt
(MRL.Cg-Ifngr1tm1Agt Faslpr)
|
decreased anti-nuclear antigen antibody level
|
J:92084
|
decreased autoantibody level
|
J:92084
|
decreased susceptibility to systemic lupus erythematosus
|
J:92084
|
Faslpr/Faslpr Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(MRL.Cg-Faslpr Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
Faslpr/Faslpr Ighmtm1Cgn/Ighmtm1Cgn
(involves: 129S2/SvPas * C57BL/6 * MRL/Mp)
|
increased autoantibody level
|
J:119584
|
Faslpr/Faslpr Il4tm1Cgn/Il4tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6J * MRL/Mp)
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased susceptibility to systemic lupus erythematosus
|
J:39600
|
Faslpr/Faslpr Il27ratm1Mak/Il27ratm1Mak
(MRL.Cg-Il27ratm1Mak Faslpr)
|
decreased anti-double stranded DNA antibody level
|
J:122148
|
decreased susceptibility to systemic lupus erythematosus
|
J:122148
|
Faslpr/Faslpr Irf1tm1Mak/Irf1+
(MRL.Cg-Irf1tm1Mak Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:114771
|
Faslpr/Faslpr Irf1tm1Mak/Irf1tm1Mak
(MRL.Cg-Irf1tm1Mak Faslpr)
|
decreased anti-double stranded DNA antibody level
|
J:114771
|
Faslpr/Faslpr Itfg2Gt(OST215121)Lex/Itfg2Gt(OST215121)Lex
(involves: 129S5/SvEvBrd * C57BL/6J * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:205951
|
increased anti-nuclear antigen antibody level
|
J:205951
|
increased susceptibility to systemic lupus erythematosus
|
J:205951
|
Faslpr/Faslpr Pou2af1tm1Pmt/Pou2af1tm1Pmt
(involves: 129P2/OlaHsd * C57BL/6 * MRL)
|
autoimmune response
|
J:125114
|
Faslpr/Faslpr Sh2d1arpl/Sh2d1arpl
(MRL/Mp-Faslpr Sh2d1arpl)
|
increased anti-nuclear antigen antibody level
|
J:126261
|
Faslpr/Faslpr Spp1tm1Rit/Spp1tm1Rit
(involves: 129S7/SvEvBrd * C57BL/6 * MRL/Mp)
|
increased anti-double stranded DNA antibody level
|
J:73396
|
increased anti-single stranded DNA antibody level
|
J:73396
|
Faslpr/Faslpr Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * 129S2/SvPas * MRL)
|
decreased autoantibody level
|
J:38492
|
Faslpr/Faslpr Tg(CD2-Foxj1)#Stlp/0
(MRL.Cg-Faslpr Tg(CD2-Foxj1)#Stlp)
|
decreased susceptibility to systemic lupus erythematosus
|
J:122222
|
increased anti-nuclear antigen antibody level
|
J:122222
|
Faslpr/Faslpr Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Faslpr Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Faslpr/Faslpr Tg(INS-Il10)#Sar/0
(NOD.Cg-Faslpr Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
Faslpr/Faslpr Tlr7tm1Flv/Y
(involves: 129S1/Sv * C57BL/6 * MRL/Mp)
|
decreased autoantibody level
|
J:113557
|
decreased susceptibility to systemic lupus erythematosus
|
J:113557
|
increased anti-chromatin antibody level
|
J:113557
|
increased autoantibody level
|
J:113557
|
Faslpr/Faslpr Tlr9tm1Aki/Tlr9tm1Aki
(B6.Cg-Tlr9tm1Aki Faslpr)
|
autoimmune response
|
J:135036
|
Faslpr/Faslpr Tlr9tm1Aki/Tlr9tm1Aki
(MRL.Cg-Tlr9tm1Aki Faslpr)
|
decreased autoantibody level
|
J:113557
|
increased autoantibody level
|
J:113557
|
increased susceptibility to systemic lupus erythematosus
|
J:113557
|
Faslpr/Faslpr Tnfrsf9tm1Byk/Tnfrsf9tm1Byk
(MRL.Cg-Tnfrsf9tm1Byk Faslpr)
|
increased anti-nuclear antigen antibody level
|
J:127197
|
increased susceptibility to systemic lupus erythematosus
|
J:127197
|
Fastheo/Fastheo
(either: (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd) or (involves: C57BL/6JAnu * C57BL/10SnSg * C57BR/cd * CBA/CaJAnu))
|
increased anti-nuclear antigen antibody level
|
J:104190
|
Fastm1Ach/Fastm1Ach Tg(GZMB-cre)1Jcb/?
(involves: C57BL/6 * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Itgax-cre,-EGFP)4097Ach/?
(Not Specified)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Fastm1Ach/Fastm1Ach Tg(Lck-cre)548Jxm/?
(involves: C57BL/6 * CBA)
|
increased anti-nuclear antigen antibody level
|
J:123556
|
Fastm1Cgn/Fastm1Cgn Cd19tm1(cre)Cgn/Cd19+ Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Cd19tm1(cre)Cgn Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Cgn/Fastm1Cgn Mogtm1(cre)Gkl/Mog+ Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Cgn/Fastm1Cgn Tg(Cd4-cre)1Cwi/0
(B6.Cg-Tg(Cd4-cre)1Cwi Fastm1Cgn)
|
increased anti-single stranded DNA antibody level
|
J:114948
|
Fastm1Cgn/Fastm1Cgn Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114741
|
Fastm1Osa/Fastm1Osa
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:32125
|
increased anti-single stranded DNA antibody level
|
J:32125
|
increased autoantibody level
|
J:32125
|
Fastm1Vbo/Fastm1Vbo Tg(Ins2-cre)25Mgn/0 Tg(Ins2-HA)165Bri/0 Tg(Tcra/Tcrb)1Vbo/0
(Not Specified)
|
increased susceptibility to autoimmune diabetes
|
J:85985
|
Faslgld/Faslgld
(C3H/HeJ-Faslgld/J)
|
increased anti-double stranded DNA antibody level
|
J:7306
|
increased anti-nuclear antigen antibody level
|
J:7306,
J:29572
|
increased autoantibody level
|
J:7306
|
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
Faslgld/Faslgld
(B6.C3-Faslgld)
|
increased anti-nuclear antigen antibody level
|
J:91058
|
increased autoantibody level
|
J:91058
|
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:153501
|
increased anti-nuclear antigen antibody level
|
J:153501
|
increased susceptibility to systemic lupus erythematosus
|
J:153501
|
Fasltm1.1Lest/Fasltm1.1Lest
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:87990
|
Fbn1tm2.1Hcd/Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
Fbn1tm3.1Hcd/Fbn1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased anti-nuclear antigen antibody level
|
J:206074
|
increased autoantibody level
|
J:206074
|
Fbn1Tsk/Fbn1+
(B6.Cg-Fbn1Tsk)
|
increased autoantibody level
|
J:21987,
J:14166
|
Fbn1Tsk/Fbn1+ Il4ratm1Sz/Il4ra+
(involves: BALB/cJ * C57BL/6J * C57BL/10 * DBA/2)
|
increased autoantibody level
|
J:68448
|
Fcer1gtm1Rav/Fcer1gtm1Rav
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
Fcer1gtm1Rav/Fcer1gtm1Rav Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:122114
|
Fcer1gtm1Tks/Fcer1gtm1Tks
(C57BL/6-Fcer1gtm1Tks)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:145432
|
Fcgr1tm1Jsv/Fcgr1tm1Jsv
(involves: 129P2/OlaHsd * BALB/c)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
decreased susceptibility to induced arthritis
|
J:83995
|
Fcgr2btm1.2Jsv/Fcgr2b+ X/Yaa
(involves: C57BL/6 * FVB/N * SB/Le)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
Fcgr2btm1.2Jsv/Fcgr2btm1.2Jsv Sle16C57BL/6/Sle16C57BL/6
(involves: C57BL/6 * FVB/N)
|
increased susceptibility to induced arthritis
|
J:179175
|
Fcgr2btm1Kgcs/Fcgr2b+
(involves: C57BL/6)
|
increased anti-chromatin antibody level
|
J:190890
|
increased anti-double stranded DNA antibody level
|
J:190890
|
increased susceptibility to induced arthritis
|
J:190890
|
Fcgr2btm1Ttk/Fcgr2btm1.2Jsv Sle21129P2/Ola/Sle21C57BL/6
(involves: 129P2/Ola * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk
(Not Specified)
|
increased susceptibility to induced arthritis
|
J:106191
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Il17atm1Yiw/Il17atm1Yiw
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129S2/SvPas * 129S4/SvJae * BALB/c)
|
increased autoantibody level
|
J:207275
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Sle21129P2/Ola/Sle21129P2/Ola
(B6.129S4-Fcgr2btm1Ttk)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
increased autoantibody level
|
J:179175
|
increased susceptibility to induced arthritis
|
J:179175
|
increased susceptibility to systemic lupus erythematosus
|
J:179175
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: 129S4/SvJae * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Tlr7tm1Flv/Y X/Yaa
(B6.Cg-Fcgr2btm1Ttk Tlr7tm1Flv Yaa)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Traf3ip2tm1Sbn/Traf3ip2+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
increased susceptibility to systemic lupus erythematosus
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk Traf3ip2tm1Sbn/Traf3ip2tm1Sbn
(involves: 129 * 129S4/SvJae * C57BL/6)
|
decreased susceptibility to systemic lupus erythematosus
|
J:191090
|
increased anti-double stranded DNA antibody level
|
J:191090
|
increased anti-nuclear antigen antibody level
|
J:191090
|
increased autoantibody level
|
J:191090
|
Fcgr2btm1Ttk/Fcgr2btm1Ttk X/Yaa
(B6.Cg-Fcgr2btm1Ttk Yaa)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
increased susceptibility to systemic lupus erythematosus
|
J:127600
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune hemolytic anemia
|
J:83995
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv
(B6.129P2-Fcgr3tm1Jsv/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126520
|
decreased susceptibility to induced arthritis
|
J:106191
|
Fcgr3tm1Jsv/Fcgr3tm1Jsv Sle21129P2/Ola/Sle21129P2/Ola
(B6.129P2-Fcgr3tm1Jsv)
|
increased anti-chromatin antibody level
|
J:179175
|
increased anti-double stranded DNA antibody level
|
J:179175
|
increased anti-histone antibody level
|
J:179175
|
increased anti-single stranded DNA antibody level
|
J:179175
|
Fcgr4tm1.1Rav/Fcgr4tm1.1Rav
(involves: C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:167375
|
Fcmrtm1Ohno/Fcmrtm1Ohno
(B6.129-Fcmrtm1Ohno)
|
increased anti-chromatin antibody level
|
J:190117
|
increased anti-double stranded DNA antibody level
|
J:190117
|
Fcrlbtm1Pdb/Fcrlbtm1Pdb
(B6.129-Fcrlbtm1Pdb)
|
increased anti-nuclear antigen antibody level
|
J:165408
|
Fen1tm3.1Bhsh/Fen1+
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:231218
|
increased anti-nuclear antigen antibody level
|
J:231218
|
increased susceptibility to autoimmune disorder
|
J:231218
|
Ffar2tm1Dgen/Ffar2tm1Dgen
(involves: C57BL/6)
|
increased susceptibility to induced arthritis
|
J:153951
|
Fgl1tm1b(EUCOMM)Hmgu/Fgl1tm1b(EUCOMM)Hmgu
(involves: BALB/cJ * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:269578
|
Flicrem1Doi/Flicrem1Doi
(NOD/ShiLtDoi-Flicrem1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:241346
|
Foxo1tm1Flv/Foxo1tm1Flv Tg(Cd4-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased anti-double stranded DNA antibody level
|
J:147057
|
increased anti-nuclear antigen antibody level
|
J:147057
|
Foxp3tm1(cre)Saka/Y
(involves: BALB/c)
|
increased autoantibody level
|
J:140085
|
Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to autoimmune disorder
|
J:82560
|
Foxp3tm1.1Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
Foxp3tm1.1Ayr/Foxp3tm1.1Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
Foxp3tm1Ayr/Y Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to autoimmune disorder
|
J:97029
|
Foxp3tm1Kuch/? Il6tm1Kopf/Il6tm1Kopf
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123352
|
Foxp3tm2.1(EGFP/cre)Shori/Y Pdcd1tm1Hon/Pdcd1tm1Hon
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:234397
|
Foxp3tm2Flv/Y
(involves: C57BL/6)
|
increased autoantibody level
|
J:118631
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3+ Gpr174tm1Cys/Gpr174+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
Foxp3tm3(HBEGF/GFP)Ayr/Foxp3tm3(HBEGF/GFP)Ayr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:117743
|
Foxp3tm4(YFP/icre)Ayr/Y Zfp91tm1Smoc/Zfp91tm1Smoc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:306129
|
Foxp3tm4(YFP/icre)Ayr/Foxp3tm4(YFP/icre)Ayr Ikzf4tm1Djr/Ikzf4tm1Djr
(involves: 129S1/Sv * 129X1/SvJ)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:294549
|
Foxp3tm8Ayr/Y
(B6.129-Foxp3tm8Ayr)
|
autoimmune response
|
J:157377
|
Fpr2tm1Rjf/Fpr2tm1Rjf
(involves: 129S/SvEv * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:159658
|
Fyntm1Yik/Fyntm1Yik
(involves: C57BL/6 * CBA)
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
Gabrb3tm2.1Geh/Gabrb3tm2.1Geh Tg(Cd4-cre)1Cwi/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:333883
|
Gadd45atm1Ajf/Gadd45atm1Ajf
(either: (involves: 129P2/OlaHsd * C57BL/6) or (involves: 129X1/SvJ * C57BL/6))
|
increased anti-double stranded DNA antibody level
|
J:76041
|
increased anti-histone antibody level
|
J:76041
|
increased anti-single stranded DNA antibody level
|
J:76041
|
increased autoantibody level
|
J:76041
|
Gadd45btm1Flv/Gadd45btm1Flv
(B6.129S6-Gadd45btm1Flv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:118837
|
Gadd45btm1Flv/Gadd45btm1Flv Gadd45gtm1Flv/Gadd45gtm1Flv
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:118837
|
increased anti-histone antibody level
|
J:118837
|
Gata1tm6Sho/Gata1tm6Sho
(C.129S1-Gata1tm6Sho)
|
autoimmune response
|
J:182213
|
Gcc2em1Cya/Gcc2em1Cya
(C57BL/6J-Gcc2em1Cya)
|
increased autoantibody level
|
J:346915
|
Ghrtm1Jjk/Ghrtm1Jjk
(involves: 129P2/OlaHsd * BALB/c)
|
decreased susceptibility to autoimmune diabetes
|
J:59132
|
Ghrhtm1Salv/Ghrhtm1Salv
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177054
|
Ghrhrlit/Ghrhrlit
(C57BL/6J-Ghrhrlit)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85381
|
Gm614tm1.1Cya/Gm614tm1.1Cya Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
decreased susceptibility to systemic lupus erythematosus
|
J:307345
|
Gna12tm1Citb/Gna12tm1Citb Gna13tm2.1Soff/Gna13tm2.1Soff Tg(Lck-cre)548Jxm/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased susceptibility to autoimmune diabetes
|
J:149560
|
Gpr132tm1Witt/Gpr132tm1Witt
(involves: 129X1/SvJ * BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:69473
|
Gpr174tm1Cys/Y
(B6.129-Gpr174tm1Cys)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
Gpr174tm1Cys/Gpr174+
(B6.129-Gpr174tm1Cys)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:222307
|
Gpsm3Gt(IST12408A1)Tigm/Gpsm3Gt(IST12408A1)Tigm
(involves: C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:193270
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:193993
|
Grk6tm1.1Mca/Grk6tm1.1Mca
(B6.129S4-Grk6tm1.1Mca)
|
increased anti-double stranded DNA antibody level
|
J:225063
|
Gt(ROSA)26Sortm1(DTA)Jpmb/Gt(ROSA)26Sor+ Tg(Plp1-cre/ERT)3Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
autoimmune response
|
J:234435
|
Gt(ROSA)26Sortm1(Ptpn22*)Draw/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased autoantibody level
|
J:201448
|
Gt(ROSA)26Sortm2.1(Cd74/MOG)Awai/Gt(ROSA)26Sor+
(involves: C57BL/6 * BALB/cJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky/Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
increased anti-double stranded DNA antibody level
|
J:133215
|
increased anti-single stranded DNA antibody level
|
J:133215
|
Gvhd4DBA/2J/Gvhd4DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
Gvhd4DBA/2J/Gvhd4DBA/2J Gvhd5DBA/2J/Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
Gvhd5DBA/2J/Gvhd5DBA/2J
(involves: C57BL/10 * DBA/2J)
|
increased anti-single stranded DNA antibody level
|
J:66655
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Rag1tm1Mom/Rag1tm1Mom Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-Rag1tm1Mom H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
increased autoantibody level
|
J:113267
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell/Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD2-CD4,HLA-DQA1,HLA-DQB1)1Ell)
|
autoimmune response
|
J:87013,
J:86540
|
decreased susceptibility to autoimmune disorder
|
J:87013
|
increased autoantibody level
|
J:113267
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell/Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell
(NOD.Cg-H2-Ab1b-tm1Gru Tg(CD4,HLA-DQA1,HLA-DQB1)N8Ell)
|
increased autoantibody level
|
J:113509
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
increased susceptibility to autoimmune diabetes
|
J:59245
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * C57BL/10SnJ * CBA)
|
increased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)70Myl)
|
increased autoantibody level
|
J:88055
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl/0
(NOD.Cg-H2-Ab1b-tm1Gru Tg(HLA-DQA1,HLA-DQB1)73Myl)
|
increased autoantibody level
|
J:88055
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(HLA-DRB1)31Dmz/0 Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Gru/H2-Ab1b-tm1Gru Tg(Ins2-CD80)3B7Flv/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
decreased susceptibility to autoimmune diabetes
|
J:68641
|
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
H2-Ab1b-tm1Wug/H2-Ab1b-tm1Wug Cd19tm1(cre)Cgn/Cd19+
(involves: 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:204951
|
H2-Ab1bm12/H2-Ab1bm12
(B6(C)-H2-Ab1bm12/KhEgJ)
|
decreased susceptibility to autoimmune disorder
|
J:100123
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:100213
|
H2-Ab1bm12/H2-Ab1bm12
(NZB.B6(C)-H2-Ab1bm12)
|
autoimmune response
|
J:4554
|
increased anti-double stranded DNA antibody level
|
J:104189
|
increased anti-erythrocyte antigen antibody level
|
J:4554
|
increased anti-single stranded DNA antibody level
|
J:104189
|
H2-Ab1g7-em1Dvs/H2-Ab1g7-em1Dvs H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-Ab1g7-em1Dvs H2-D1em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em1Dvs/H2-D1b-em1Dvs
(NOD/ShiLtDvs-H2-D1b-em1Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em2Dvs/H2-D1b-em2Dvs
(NOD/ShiLtDvs-H2-D1b-em2Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em3Dvs/H2-D1b-em3Dvs
(NOD/ShiLtDvs-H2-D1b-em3Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em4Dvs/H2-D1b-em4Dvs
(NOD/ShiLtDvs-H2-D1b-em4Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs Tg(HLA-A/H2-D/B2M)1Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-A/H2-D/B2M)1Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-em5Dvs/H2-D1b-em5Dvs H2-K1d-em1Dvs/H2-K1d-em1Dvs Tg(HLA-B39/H2-D/B2m)2Dvs/?
(NOD/ShiLtDvs-H2-K1d-em1Dvs H2-D1b-em5Dvs Tg(HLA-B39/H2-D/B2M)2Dvs/Dvs)
|
autoimmune response
|
J:257229
|
increased susceptibility to autoimmune diabetes
|
J:257229
|
H2-D1b-tm1Bpe/H2-D1b-tm1Bpe H2-K1b-tm1Bpe/H2-K1b-tm1Bpe X/Yaa
(BXSB.129P2(B6)-H2-K1b-tm1Bpe H2-D1b-tm1Bpe/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
H2-DMatm1Luc/H2-DMatm1Luc
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:72243
|
H2-DMatm1Luc/H2-DMatm1Luc
(B6.129S4-H2-Dmatm1Luc)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:125654
|
H2-K1d-em4Dvs/H2-K1d-em4Dvs
(NOD/ShiLtDvs-H2-K1d-em4Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-K1d-em5Dvs/H2-K1d-em5Dvs
(NOD/ShiLtDvs-H2-K1d-em5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-K1d-em7Dvs/H2-K1d-em7Dvs
(NOD/ShiLtDvs-H2-K1d-em7Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:257229
|
H2-T23tm1Cant/H2-T23tm1Cant
(involves: 129S6/SvEvTac * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89808
|
H2-T23tm2Cant/H2-T23tm2Cant
(B6.129S6-H2-T23tm2Cant)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2-T23tm2Cant/H2-T23tm2Cant Tg(Tcra2D2,Tcrb2D2)1Kuch/?
(involves: 129S6/SvEvTac)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2-T23tm3Cant/H2-T23tm3Cant
(B6.129S6-H2-T23tm3Cant)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:142087
|
H2b/H2b
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2b/H2d
((C57BL/6 x DBA/2)F1)
|
increased autoantibody level
|
J:106141
|
H2b/H2g7
(NOD.B10SnJ-H2b)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2b/H2g7 Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
rheumatoid arthritis
|
J:36815,
J:275827
|
H2d/H2d
(DBA/2)
|
increased autoantibody level
|
J:106141
|
H2dlAb1-Ea/H2dlAb1-Ea Tg(HLA-DRA,HLA-DRB5*0101)hiKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
H2dlAb1-Ea/H2dlAb1-Ea Tg(HLA-DRA,HLA-DRB5*0101)loKito/0 Tg(TRATL3A6,TRBTL3A6)#Kito/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:189816
|
H2g7/H2g7 Ins2tm1Jja/Ins2tm1Jja Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
H2g7/H2g7 Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
H2g7/H2g7 Tg(Ins2-Vtcn1)#Xxz/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: C57BL/6 * NOD * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:177612
|
H2g7/H2g7 Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(B6.NOD-(D17Mit21-D17Mit10) Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:167508
|
H2g7/H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(B6.Cg-H2g7 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
H2g7/H2g7 Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
H2g7/H2q Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
H2h2/H2g7
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2h2/H2h2
(NOD.Cg-H2h2)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2h4/H2g7
(NOD.Cg-H2h4)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2h4/H2h4
(NOD.Cg-H2h4)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i5/H2g7
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i5/H2i5
(NOD.Cg-H2i5)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i7/H2g7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2i7/H2i7
(NOD.Cg-H2i7)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2k/H2g7
(NOD.Cg-H2k)
|
decreased susceptibility to autoimmune diabetes
|
J:14178
|
H2k/H2k
(NOD.Cg-H2k)
|
increased susceptibility to autoimmune diabetes
|
J:14178
|
H2q/? Ncf1m1J/Ncf1m1J
(B6.Cg-Ncf1m1J H2q)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92437
|
increased susceptibility to induced arthritis
|
J:92437
|
rheumatoid arthritis
|
J:92437
|
H2q/H2q Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:111874
|
H2u/H2u Rag1tm1Mom/Rag1tm1Mom Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: 129S7/SvEvBrd * C57BL/6 * PL/J) or (involves: 129S7/SvEvBrd * C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
H2u/H2u Tg(Tcra19,Tcrb19)#Stl/0
(either: (involves: C57BL/6 * PL/J) or (involves: C57BL/6 * C57BL/10 * PL/J))
|
increased susceptibility to autoimmune disorder
|
J:19795
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:19795
|
H2u/H2u Tg(TCRA)B1Jg/? Tg(TCRB)C14Jg/?
(involves: C57BL/6 * C57BL/10SnSg * DBA/2 * PL/J)
|
increased autoantibody level
|
J:92991
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92991
|
Havcr1tm1Kuch/Havcr1tm1Kuch
(B6.Cg-Havcr1tm1Kuch)
|
autoimmune response
|
J:186484
|
increased anti-double stranded DNA antibody level
|
J:186484
|
Hc0/Hc0 Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
decreased susceptibility to induced arthritis
|
J:134111
|
Hc1/? Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Hcsttm1.1Dnax/Hcsttm1.1Dnax
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148086
|
Hif1atm3Rsjo/Hif1atm3Rsjo Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
decreased susceptibility to induced arthritis
|
J:107682
|
Hmox1tm1.1Gkl/Hmox1tm1.1Gkl Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:148498
|
HrUSP/HrUSP
(either: (involves: A/J * BALB/c) or (involves: BALB/c * C57BL/6) or (involves: BALB/c * DBA/2))
|
increased susceptibility to autoimmune disorder
|
J:21316
|
Hrh3Eae8-r/?
(B10.S-H2s/SgMcdJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:34892
|
Hrh3Eae8-r/Hrh3Eae8-r
(involves: B10.S/DvTe * SJL/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Hrh3Eae8-s/?
(involves: B10.S * SJL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:49054
|
Hrh3tm1Twl/Hrh3tm1Twl
(B6.129X1-Hrh3tm1Twl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:122269
|
Hspa13tm1.1Smoc/Hspa13tm1.1Smoc Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S * C57BL/6)
|
decreased autoantibody level
|
J:303927
|
Ica1tm1Mdos/Ica1tm1Mdos
(NOD.129-Ica1tm1Mdos)
|
decreased susceptibility to autoimmune diabetes
|
J:83526
|
Icam1tm1Jcgr/Icam1tm1Jcgr Tg(INS-Il10)#Sar/0
(NOD.Cg-Icam1tm1Jcgr Tg(INS-Il10)#Sar)
|
decreased susceptibility to autoimmune diabetes
|
J:66103
|
Icostm1Flv/Icostm1Flv
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:87123
|
Icostm1Flv/Icostm1Flv
(NOD.129S1-Icostm1Flv)
|
decreased anti-insulin autoantibody level
|
J:131529
|
decreased autoantibody level
|
J:131529
|
decreased susceptibility to autoimmune diabetes
|
J:131529
|
Id3tm1Zhu/Id3tm1Zhu
(involves: 129S4/SvJaeSor)
|
increased autoantibody level
|
J:93916
|
Idd3A/J/Idd3A/J
(NOD.A-Idd3A/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3C57BL/6/Idd3C57BL/6
(NOD.B6-Idd3C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3CAST/EiJ/Idd3CAST/EiJ
(NOD.CAST-Idd3CAST/EiJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3CZECHI/EiJ/Idd3CZECHI/EiJ
(NOD.CZECH-Idd3CZECHI/EiJ)
|
decreased susceptibility to autoimmune diabetes
|
J:120349
|
Idd3SWR/J/Idd3SWR/J
(NOD.SWR-Idd3SWR/J)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Idd4.3C57L/Idd4.3C57L
(involves: C57L/J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:118951
|
Idd6.1C3H/HeJ/Idd6.1C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Idd6.2C3H/HeJ/Idd6.2C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Idd6.3C3H/HeJ/Idd6.3C3H/HeJ
(involves: C3H/HeJ * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:115021
|
Ifih1Rgsc422/Ifih1+
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
autoimmune response
|
J:209917
|
increased anti-double stranded DNA antibody level
|
J:209917
|
increased anti-nuclear antigen antibody level
|
J:209917
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
Ifih1Rgsc422/Ifih1Rgsc422
(D2JJcl.B6JJcl-Ifih1Rgsc422)
|
increased susceptibility to systemic lupus erythematosus
|
J:209917
|
Ifnb1tm1Tl/Ifnb1tm1Tl
(B10.129P2-Ifnb1tm1Tl)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83021
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.129S7-Ifngtm1Ts)
|
abnormal susceptibility to autoimmune disorder
|
J:33427
|
decreased susceptibility to autoimmune diabetes
|
J:95105
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.Cg-Ifngtm1Ts Prkdcscid)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Ifngtm1Ts/Ifngtm1Ts
(NOD.129S7(B6)-Ifngtm1Ts/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:34161
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * DBA/1 * MRL/Mp)
|
decreased anti-double stranded DNA antibody level
|
J:39600
|
decreased anti-nuclear antigen antibody level
|
J:39600
|
decreased autoantibody level
|
J:39600
|
decreased susceptibility to autoimmune disorder
|
J:39600
|
Ifngtm1Ts/Ifngtm1Ts
(involves: 129S7/SvEvBrd * A/WySn * C57BL/10SnSg * Swiss)
|
decreased susceptibility to autoimmune disorder
|
J:119207
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:38363
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:53577
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:99347
|
Ifngr1tm1Agt/Ifngr1tm1Agt
(involves: 129S7/SvEvBrd * DBA/1OlaHsd)
|
increased susceptibility to induced arthritis
|
J:40634
|
Ifngr2tm1Pbro/Ifngr2tm1Pbro
(NOD.129S1-Ifngr2tm1Pbro)
|
decreased susceptibility to autoimmune diabetes
|
J:72818
|
Igh-7tm1Led/Igh-7tm1Led Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
Igh-Jtm1(CB20)Riho/Igh-J+
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
Igh-Jtm1(CB20)Riho/Igh-Jtm1(CB20)Riho
(involves: C57BL/10 * DBA/1)
|
increased susceptibility to induced arthritis
|
J:179456
|
Igh-Jtm1Aigl/Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
Igh-Jtm1Aigl/Igh-J+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:111543
|
Igh-Jtm1Aigl/Igh-J+ Mogtm1Dpd/Mogtm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Igh-Jtm1Aigl/Igh-J+ Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Igh-Jtm1Aigl/Igh-Jtm1Aigl Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N * SJL/J)
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:131138
|
Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.129P2-Igh-Jtm2(3H9-VDJ*)Mwg)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Igh-Jtm3(3H9-VDJ*)Mwg/Igh-Jtm3(3H9-VDJ*)Mwg
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:126940
|
Ightm1(Ighppc1-5)Cche/Igh+
(B6.Cg-Ightm1(Ighppc1-5)Cche)
|
increased autoantibody level
|
J:138356
|
Ightm2.1Hws/Ightm2.1Hws
(involves: BALB/c)
|
increased anti-nuclear antigen antibody level
|
J:142069
|
Ighg1em1Wliu/Ighg1em1Wliu
(C57BL/6-Ighg1em1Wliu)
|
increased anti-double stranded DNA antibody level
|
J:266937
|
increased anti-nuclear antigen antibody level
|
J:266937
|
increased autoantibody level
|
J:266937
|
Ighmtm1Cgn/Ighm+
(NOD.129S2-Ighmtm1Cgn)
|
increased susceptibility to autoimmune diabetes
|
J:37287
|
Ighmtm1Cgn/Ighm+ Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.Cg-Ighmtm1Cgn Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
Ighmtm1Cgn/Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn)
|
decreased susceptibility to autoimmune diabetes
|
J:37287
|
Ighmtm1Cgn/Ighmtm1Cgn
(involves: 129S2/SvPas)
|
increased susceptibility to induced arthritis
|
J:157619
|
Ighmtm1Cgn/Ighmtm1Cgn
(NOD.129S2-Ighmtm1Cgn/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/?
(NODCaj.Cg-Ighmtm1Cgn Tg(Igh-VB1-8/Igh-6m)1Mjsk/FswJ)
|
increased susceptibility to autoimmune diabetes
|
J:93190
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn X/Yaa
(BXSB.129S2(B6)-Ighmtm1Cgn/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:206236
|
Ighmtm1Msn/Ighmtm1Msn
(involves: 129S/SvEv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:111817
|
increased autoantibody level
|
J:111817
|
Igktm1Dhu/Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca/0 Tg(TcraS106-1,TcrbS106-1)TS1SWAjca/0
(C.Cg-Igktm1Dhu Tg(H2-Ea-HA)HACIIAjca Tg(TcraS106-1,TcrbS106-1)TS1SWAjca)
|
decreased susceptibility to autoimmune disorder
|
J:209872
|
Igkrstm1Nemz/Igkrstm1Nemz Tg(BCL2)22Wehi/?
(involves: 129 * C57BL)
|
increased anti-double stranded DNA antibody level
|
J:132125
|
Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
autoimmune response
|
J:81805
|
increased anti-double stranded DNA antibody level
|
J:81805
|
increased anti-histone antibody level
|
J:81805
|
increased anti-nuclear antigen antibody level
|
J:81805
|
increased anti-single stranded DNA antibody level
|
J:81805
|
increased autoantibody level
|
J:81805,
J:50626
|
Ikzf4tm1.1Etms/Ikzf4tm1.1Etms
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:295208
|
Il1atm1Yiw/Il1atm1Yiw Il1btm1Yiw/Il1btm1Yiw
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165513
|
Il1btm1Lvp/Il1btm1Lvp
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune myasthenia gravis
|
J:67001
|
Il1r1em1Qizh/Il1r1em1Qizh
(C57BL/6-Il1r1em1Qizh)
|
increased susceptibility to induced arthritis
|
J:338375
|
Il1r1tm1Imx/Il1r1tm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
Il1r1tm1Imx/Il1r1tm1Imx
(B6.129S7-Il1r1tm1Imx/J)
|
increased susceptibility to induced arthritis
|
J:125570
|
Il1r1tm1Imx/Il1r1tm1Imx Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
Il1r1tm1Imx/Il1r1tm1Imx Vsig4tm1Gne/Vsig4tm1Gne
(B6.Cg-Il1r1tm1Imx Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
Il1r1tm1Roml/Il1r1tm1Roml
(NOD.Cg-Il1r1tm1Roml)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
Il1r1tm1Roml/Il1r1tm1Roml
(involves: 129S1/Sv)
|
decreased susceptibility to induced arthritis
|
J:120707
|
Il1r2tm1Yiw/Il1r2tm1Yiw
(B6.129P2-Il1r2tm1Yiw)
|
increased susceptibility to induced arthritis
|
J:274653
|
Il1rntm1.1Cga/Il1rntm1.1Cga Lyz2tm1(cre)Ifo/Lyz2+
(D1.Cg-Il1rntm1.1Cga Lyz2tm1(cre)Ifo)
|
increased susceptibility to induced arthritis
|
J:162760
|
Il1rntm1Nick/Il1rntm1Nick
(involves: BALB/cAnNHsd)
|
rheumatoid arthritis
|
J:89034
|
Il1rntm1Nick/Il1rntm1Nick
(involves: BALB/cAnNHsd * C57BL/6)
|
rheumatoid arthritis
|
J:89034
|
Il1rntm1Yiw/Il1rntm1Yiw
(C.129-Il1rntm1Yiw)
|
rheumatoid arthritis
|
J:143719
|
Il1rntm1Yiw/Il1rntm1Yiw Il17atm1Yiw/Il17a+
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
Il2tm1.1Flv/Il2tm1.1Flv
(NOD/ShiLtJ-Il2tm1.1Flv)
|
abnormal susceptibility to autoimmune disorder
|
J:150823
|
Il2tm1Hor/Il2+
(NOD.129P2(B6)-Il2tm1Hor/DvsJ)
|
increased susceptibility to autoimmune diabetes
|
J:120349
|
Il2tm1Hor/Il2tm1Hor
(C.129P2-Il2tm1Hor)
|
increased susceptibility to autoimmune hemolytic anemia
|
J:29799
|
Il2tm1Hor/Il2tm1Hor
(B6.129P2-Il2tm1Hor/J)
|
increased susceptibility to autoimmune disorder
|
J:113547
|
Il2rbtm1Mak/Il2rbtm1Mak
(either: (involves: 129P2/OlaHsd) or (involves: 129S2/SvPas))
|
increased anti-nuclear antigen antibody level
|
J:25940
|
increased susceptibility to autoimmune hemolytic anemia
|
J:25940
|
Il2rbtm1Mak/Il2rbtm1Mak
(B6.129-Il2rbtm1Mak)
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
Il2rbtm1Mak/Il2rbtm1Mak
(C.129-Il2rbtm1Mak)
|
increased anti-double stranded DNA antibody level
|
J:113547
|
increased susceptibility to autoimmune hemolytic anemia
|
J:113547
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
Il4/Il13tm3Anjm/Il4/Il13tm3Anjm
(C.129P2/OlaHsd-Il4/Il13tm3Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
Il4tm1Cgn/Il4tm1Cgn
(NOD.129P2-Il4tm1Cgn)
|
decreased susceptibility to autoimmune disorder
|
J:95105
|
increased susceptibility to autoimmune disorder
|
J:95105
|
Il4tm1Cgn/Il4tm1Cgn
(either: NOD.129-Il4tm1Cgn or (involves: 129 * NOD))
|
autoimmune response
|
J:85924
|
Il4tm1Cgn/Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Il4tm1Cgn Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:85924
|
Il4tm1Kopf/Il4tm1Kopf Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
Il4tm1Nnt/Il4tm1Nnt
(involves: C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:91403
|
Il4tm2Nnt/Il4tm2Nnt
(BALB/c-Il4tm2Nnt/J)
|
decreased susceptibility to autoimmune disorder
|
J:141937
|
Il5ratm1Ktk/Il5ratm1Ktk Lyntm1Tya/Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:91089
|
Il6tm1Kopf/Il6tm1Kopf
(B6.129S2-Il6tm1Kopf/J)
|
decreased susceptibility to induced arthritis
|
J:208213
|
Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:142883
|
Il6sttm1Thir/Il6sttm1Thir
(involves: 129 * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:133059
|
increased anti-nuclear antigen antibody level
|
J:133059
|
increased anti-single stranded DNA antibody level
|
J:133059
|
increased autoantibody level
|
J:133059
|
rheumatoid arthritis
|
J:133059
|
Il9rtm1Jcrd/Il9rtm1Jcrd
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151907
|
Il10raNZW/Il10ra+
((NZB x NZW)F1)
|
increased anti-chromatin antibody level
|
J:102087
|
Il10ratm1.1Tlg/Il10ratm1.1Tlg Tg(Cd4-cre)1Cwi/?
(B6.Cg-Tg(Cd4-cre)1Cwi Il10ratm1.1Tlg)
|
autoimmune response
|
J:189797
|
Il12atm1Cab/Il12atm1Cab Il23atm1.1Thak/Il23atm1.1Thak
(B6.Cg-Il12atm1Cab Il23atm1.1Thak)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
increased anti-nuclear antigen antibody level
|
J:106805
|
Il13tm1.1Anjm/Il13tm1.1Anjm
(C.129P2-Il13tm1.1Anjm)
|
decreased susceptibility to autoimmune disorder
|
J:141937,
J:91403
|
Il13tm2Anjm/Il13tm2Anjm
(B6.129P2-Il13tm2Anjm)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:131969
|
Il15tm1Imx/Il15tm1Imx X/Yaa
(BXSB.B6-Il15tm1Imx/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Il17atm1Cdon/Il17atm1Cdon
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
Il17atm1Yiw/Il17atm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129P2/OlaHsd * BALB/cA * C57BL/6J)
|
decreased susceptibility to induced arthritis
|
J:83408
|
Il17atm1Yiw/Il17atm1Yiw Il17ftm1Yiw/Il17ftm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
Il17atm1Yiw/Il17atm1Yiw Tg(CD2-Rorc)#Staka/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:230700
|
Il17ctm1.1Cdon/Il17ctm1.1Cdon
(involves: 129S6/SvEvTac)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
Il17ftm1Cdon/Il17ftm1Cdon
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136279
|
Il17ftm1Yiw/Il17ftm1Yiw Il1rntm1Yiw/Il1rntm1Yiw
(involves: 129 * BALB/c)
|
rheumatoid arthritis
|
J:143719
|
Il17rctm1Lex/Il17rctm1Lex
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:159874
|
Il21tm1Lex/Il21tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:123351
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
Il21rtm1Kopf/Il21rtm1Kopf
(B6.129-Il21rtm1Kopf)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137377
|
Il21rtm1Wjl/Il21rtm1Wjl
(NOD.Cg-Il21rtm1Wjl)
|
decreased susceptibility to autoimmune diabetes
|
J:139075
|
Il21rtm1Wjl/Il21rtm1Wjl X/Yaa
(BXSB.129(Cg)-Il21rtm1Wjl/Dcr)
|
decreased susceptibility to systemic lupus erythematosus
|
J:144484
|
Il23atm1.1Thak/Il23atm1.1Thak
(C57BL/6-Il23atm1.1Thak)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:143970
|
Il23atm1Dnax/Il23atm1Dnax
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:95542
|
Il23rtm1Kuch/Il23rtm1Kuch
(C57BL/6-Il23rtm1Kuch)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:148248
|
Il25tm1Dart/Il25tm1Dart
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:125296
|
Il27tm1Cua/Il27tm1Cua
(C57BL/6-Il27tm1Cua)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:147706
|
Il27ratm1Mak/Il27ratm1Mak
(B6.129P2-Il27ratm1Mak)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116610
|
Il27ratm1Mak/Il27ratm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:151552
|
Imh1NZB/Imh1NZB
(involves: NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:26266
|
Imh1NZB/Imh1NZW
(involves: NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:22353
|
Inpp5dtm1Rav/Inpp5dtm1Rav Cd79atm1(cre)Reth/Cd79a+ Tg(IghAb36-65)1Wys/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
increased autoantibody level
|
J:178833
|
Ins1tm1Jja/Ins1tm1Jja
(NOD.129S2-Ins1tm1Jja)
|
decreased susceptibility to autoimmune diabetes
|
J:85309
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)1Ell)
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
decreased anti-insulin autoantibody level
|
J:98583
|
decreased susceptibility to autoimmune diabetes
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Ins2tm1Mnt/Ins2tm1Mnt Tg(Aire-cre)1Mnt/0
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased anti-insulin autoantibody level
|
J:152798
|
Ins1tm1Jja/Ins1tm1Jja Tg(Ins2*Y16A)1Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Ins1tm1Jja/Ins1tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins1tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
Ins2C95S/Ins2+
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
Ins2C95S/Ins2C95S
(C3HeB/FeJ-Ins2C95S)
|
increased susceptibility to autoimmune diabetes
|
J:122098
|
Ins2tm1Jja/Ins2tm1Jja
(NOD.129S2-Ins2tm1Jja)
|
increased anti-insulin autoantibody level
|
J:85309
|
Ins2tm1Jja/Ins2tm1Jja Tg(Ins2*Y16A)3Ell/0
(NOD.Cg-Ins2tm1Jja Tg(Ins2*Y16A)3Ell)
|
autoimmune response
|
J:98583
|
increased anti-insulin autoantibody level
|
J:98583
|
Irak1tm1Jth/Y
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
Irak1tm1Jth/Irak1tm1Jth
(B6.Cg-Irak1tm1Jth)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:82302
|
Irak3tm1Flv/Irak3tm1Flv
(NOD.129S1(B6)-Irak3tm1Flv)
|
increased anti-insulin autoantibody level
|
J:229884
|
increased susceptibility to autoimmune diabetes
|
J:229884
|
Irf1tm1Cwe/Irf1tm1Cwe
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:43086
|
Irf1tm1Cwe/Irf1tm1Cwe
(involves: 129)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:84367
|
Irs1tm1Mfw/Irs1tm1Mfw Irs2tm2Mfw/Irs2tm2Mfw Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137845
|
Irs1tm2Tka/Irs1tm2Tka Irs2tm2Tka/Irs2tm2Tka Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased susceptibility to autoimmune diabetes
|
J:137846
|
Itgavtm2Hyn/Itgavtm2.1Hyn Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * FVB)
|
increased autoantibody level
|
J:125508
|
Itgavtm2Hyn/Itgavtm2.1Hyn Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
increased autoantibody level
|
J:125508
|
Itgaxtm1Bll/Itgaxtm1Bll
(B6.129S7-Itgaxtm1Bll)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:122187
|
Itgb2tm1Bay/Itgb2tm1Bay Psrs1PL/J/Psrs1PL/J
(B6.Cg-(D10Mit126-D10Mit38) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
Itgb2tm1Bay/Itgb2tm1Bay Psrs1PL/J/Psrs1PL/J
(B6.Cg-(D10Mit75-D10Mit271) Itgb2tm1Bay)
|
rheumatoid arthritis
|
J:134251
|
Jak1M1Mhda/Jak1+
(C3HeB/FeJ-Jak1M1Mhda)
|
increased anti-nuclear antigen antibody level
|
J:199153
|
Junbtm3Wag/Junbtm3Wag Tg(KRT5-cre)1Tak/0
(involves: 129/Sv * 129P2/OlaHsd * C3H * C57BL/6)
|
increased anti-histone antibody level
|
J:155575
|
increased susceptibility to systemic lupus erythematosus
|
J:155575
|
KitW-sh/KitW-sh Lyntm1Ard/Lyntm1Ard
(involves: 101 * 129P2/OlaHsd * C3H/HeH)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
KitW/KitW-v
((WB KitW x B6.Cg-KitW-v)F1)
|
decreased susceptibility to induced arthritis
|
J:178942
|
Ksr1tm1Shaw/Ksr1tm1Shaw
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:140520
|
Lag3tm1Daav/Lag3+ Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
Lag3tm1Daav/Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs/0
(NOD.Cg-Lag3tm1Daav Tg(Foxp3-EGFP/cre)1cJbs)
|
decreased susceptibility to autoimmune diabetes
|
J:260063
|
Laq1MRL/Laq1MRL
(involves: C57BL/6 * MRL)
|
increased susceptibility to autoimmune disorder
|
J:45708
|
Lat2tm1Mal/Lat2tm1Mal
(B6.129S2-Lat2tm1Mal)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
Lat2tm1Mal/Lat2tm1Mal Lime1tm1.1Mal/Lime1tm1.1Mal
(involves: 129 * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:126321
|
Lat2tm1Wz/Lat2tm1Wz
(B6.Cg-Lat2tm1Wz)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased autoantibody level
|
J:116157
|
Lat2tm2Wz/Lat2tm2Wz Tg(Lck-cre)548Jxm/0
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
Lattm1.1Lov/Lattm1.1Lov
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
increased anti-nuclear antigen antibody level
|
J:77099
|
increased autoantibody level
|
J:77099
|
Lattm1.1Lov/Lattm1.1Lov Lat2tm1Wz/Lat2tm1Wz
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:116157
|
Lattm1.1Mal/Lattm1.1Mal
(involves: 129S2/SvPas)
|
increased anti-chromatin antibody level
|
J:125722
|
increased anti-erythrocyte antigen antibody level
|
J:125722
|
increased anti-nuclear antigen antibody level
|
J:125722
|
increased susceptibility to autoimmune hemolytic anemia
|
J:125722
|
Lbric-J/Lbr+
((NZW/LacJ x C57BL/6J-Lbric-J/J)F1)
|
increased anti-chromatin antibody level
|
J:234168
|
increased anti-nuclear antigen antibody level
|
J:234168
|
increased autoantibody level
|
J:234168
|
increased susceptibility to systemic lupus erythematosus
|
J:234168
|
Lbw2NZB/BlScr/Lbw2NZB/BlScr
(involves: NZB * NZW)
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
Lbw2NZB/BlScr/Lbw2NZW/LacScr
(involves: NZB * NZW)
|
increased anti-chromatin antibody level
|
J:98150
|
increased autoantibody level
|
J:98150
|
Lbw2NZW/LacScr/Lbw2NZW/LacScr
(involves: NZB * NZW)
|
decreased autoantibody level
|
J:98150
|
Lbw5NZW/LacScr/Lbw5NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw5NZW/LacScr/Lbw5NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw6NZW/LacScr/Lbw6NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw7NZB/BlScr/Lbw7NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw7NZB/BlScr/Lbw7NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to systemic lupus erythematosus
|
J:20991
|
Lbw8NZB/BlScr/Lbw8NZB/BlScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
Lbw8NZB/BlScr/Lbw8NZW/LacScr
(involves: NZB/BlScr * NZW/LacScr)
|
increased susceptibility to autoimmune disorder
|
J:20991
|
Lcp2twm/Lcp2twm
(C57BL/6JSfdAnu-Lcp2twm/Anu)
|
autoimmune response
|
J:104190
|
Lctlp1FVB/NJ/Lctlp1FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
Lctlp2FVB/NJ/Lctlp2FVB/NJ
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:122919
|
Leprdb/Leprdb
(involves: C57BLKS/J)
|
increased susceptibility to autoimmune diabetes
|
J:7005
|
Lgals1tm1Rob/Lgals1tm1Rob
(involves: 129S/SvEv)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:123416
|
Lgals9tm1Glp/Lgals9tm1Glp
(B6.129S6-Lgals9tm1Glp)
|
increased susceptibility to induced arthritis
|
J:132889
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased anti-chromatin antibody level
|
J:157574
|
increased anti-double stranded DNA antibody level
|
J:157574
|
ll/ll X/Yaa
(BXSB/MpJScr-ll)
|
decreased anti-nuclear antigen antibody level
|
J:10973
|
decreased susceptibility to autoimmune disorder
|
J:10973
|
Lmb1C57BL/6Scr/Lmb1C57BL/6Scr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb1C57BL/6Scr/Lmb1MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb2C57BL/6Scr/Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lmb2MRL/MpScr/Lmb2MRL/MpScr
(involves: C57BL/6-Faslpr * MRL-Faslpr)
|
increased anti-double stranded DNA antibody level
|
J:45708
|
Lrch1em1Hwa/Lrch1em1Hwa
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased susceptibility to induced arthritis
|
J:115034
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(involves: 129/Sv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
Lta/Tnftm1Eug/Lta/Tnftm1Eug
(B6.129-Lta/Tnftm1Eug)
|
decreased susceptibility to induced arthritis
|
J:115034
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Lta/Tnftm1Jods/Lta/Tnftm1Jods
(C57BL/6-Lta/Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:108446
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(involves: 129S4/SvJaeSor)
|
decreased susceptibility to induced arthritis
|
J:131779
|
Ltb4r1tm1Bodd/Ltb4r1tm1Bodd
(either: (involves: 129S4/SvJaeSor * BALB/c ) or (involves: 129S4/SvJaeSor * C57BL/6))
|
decreased susceptibility to induced arthritis
|
J:163271
|
Ltb4r2tm1Bodd/Ltb4r2tm1Bodd
(involves: 129S4/SvJaeSor * C57BL/6)
|
decreased susceptibility to induced arthritis
|
J:163271
|
Ltc4stm1Blam/Ltc4stm1Blam
(C.129S7-Ltc4stm1Blam)
|
autoimmune response
|
J:182213
|
Lxw1BXSB/Scr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
Lxw3NZW/LacScr/?
(involves: BXSB/Scr * NZW/LacScr)
|
increased anti-chromatin antibody level
|
J:86924
|
Lynmld4/Lynmld4
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:144799
|
Lyntm1.1Calo/Lyntm1.1Calo Tg(Itgax-cre)1-1Reiz/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased autoantibody level
|
J:200745
|
Lyntm1Ard/Lyntm1Ard
(involves: 129P2/OlaHsd)
|
increased anti-double stranded DNA antibody level
|
J:161523
|
increased anti-nuclear antigen antibody level
|
J:161523
|
Lyntm1Ard/Lyntm1Ard
(B6.129P2-Lyntm1Ard)
|
increased anti-double stranded DNA antibody level
|
J:144799
|
increased anti-nuclear antigen antibody level
|
J:144799
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJae)
|
increased anti-double stranded DNA antibody level
|
J:42037
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor)
|
increased anti-double stranded DNA antibody level
|
J:146161
|
increased autoantibody level
|
J:200745
|
Lyntm1Sor/Lyntm1Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:71174
|
increased susceptibility to systemic lupus erythematosus
|
J:71174
|
Lyntm1Tya/Lyntm1Tya
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:29751
|
Lynweeb/Lynweeb
(C57BL/6-Lynweeb)
|
increased anti-double stranded DNA antibody level
|
J:146161
|
Lyz2tm1(cre)Ifo/Lyz2tm1(cre)Ifo Nrrostm1Wouy/Nrrostm1Wouy
(involves: 129P2/OlaHsd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
Map4k1tm1Tht/Map4k1tm1Tht
(B6.129S7-Map4k1tm1Tht)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:116613
|
Map4k3Gt(RRO270)Byg/Map4k3Gt(RRO270)Byg
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177642
|
Mapk3tm1Gela/Mapk3tm1Gela
(either: 129(Cg)-Mapk3tm1Gela or B6.129-Mapk3tm1Gela)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:107504
|
Mapk11tm1Jda/Mapk11tm1Jda Mapk14tm1Jda/Mapk14tm1Jda
(involves: 129 * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:165966
|
decreased susceptibility to induced arthritis
|
J:165966
|
Mbpshi/Mbpshi
(involves: BALB/c * C3HeB/Fe * SWV)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:48412
|
Mcph1Tg(HLA-A2.1)1Enge/Mcph1+
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
Mcph1Tg(HLA-A2.1)1Enge/Mcph1Tg(HLA-A2.1)1Enge
(NOD.B6-Mcph1Tg(HLA-A2.1)1Enge)
|
increased susceptibility to autoimmune diabetes
|
J:109851
|
Mertktm1Gkm/Mertktm1Gkm
(NOD.129P2-Mertktm1Gkm)
|
decreased susceptibility to autoimmune diabetes
|
J:147153
|
Mertktm1Gkm/Mertktm1Gkm
(B6.129P2-Mertktm1Gkm)
|
decreased autoantibody level
|
J:136377
|
Mex3btm1.1Mbld/Mex3btm1.1Mbld Plekha5Tg(AMH-cre)1Flor/Plekha5+
(involves: C57BL/6 * SJL)
|
increased anti-sperm antibody level
|
J:213588
|
Mfge8tm1Osa/Mfge8tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:225063
|
Mfge8tm1Osa/Mfge8tm1Osa Timd4tm1Osa/Timd4tm1Osa
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:187181
|
increased anti-nuclear antigen antibody level
|
J:187181
|
Mir125atm1Smoc/Mir125atm1Smoc
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
Mir140tm1.1Asah/Mir140tm1.1Asah
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased susceptibility to induced arthritis
|
J:160358
|
Mir146tm1.1Lfl/Mir146tm1.1Lfl Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:266124
|
Mir146tm2.1Bal/Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased anti-double stranded DNA antibody level
|
J:173671
|
Mir155tm1.1Rsky/Mir155tm1.1Rsky
(B6.Cg-Mir155tm1Rsky/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
Mir210tm1.1Wtsi/Mir210tm1.1Wtsi
(involves: C57BL/6J * C57BL/6N)
|
increased anti-chromatin antibody level
|
J:205868
|
increased anti-double stranded DNA antibody level
|
J:205868
|
increased anti-nuclear antigen antibody level
|
J:205868
|
Mirc33tm1.1Cwh/Mirc33tm1.1Cwh
(involves: 129X1/SvJ)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:189763
|
Mmdtm1Beij/Mmdtm1Beij
(Not Specified)
|
decreased susceptibility to induced arthritis
|
J:304637
|
Mmp2tm1Ito/Mmp2tm1Ito
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:94099
|
Mmp9tm1Arnd/Mmp9tm1Arnd
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:58833
|
Mmp9tm1Tvu/Mmp9tm1Tvu
(C3N.129S6-Mmp9tm1Tvu)
|
decreased susceptibility to induced arthritis
|
J:150311
|
Mogtm1(cre)Gkl/Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(C57BL/6-Mogtm1(cre)Gkl Tg(Tcra2D2,Tcrb2D2)1Kuch)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Dpd/Mogtm1Dpd
(B6.129S2-Mogtm1Dpd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:85155
|
Mogtm1Dpd/Mogtm1Dpd Rag2tm1Cgn/Rag2tm1Cgn Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Dpd/Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.Cg-Mogtm1Dpd Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Mogtm1Dpd/Mogtm1Dpd Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:151335
|
Mogtm1Reid/Mogtm1Reid
(B6.129S1/Sv-Mogtm1Reid)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
Mogtm1Reid/Mogtm1Reid
(129/Sv-Mogtm1Reid)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:86663
|
Mpgtm1Lds/Mpgtm1Lds
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:118148
|
decreased susceptibility to autoimmune diabetes
|
J:118148
|
Mpotm1Lus/Mpotm1Lus
(involves: 129X1/SvJ * C57BL/6J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:102965
|
Mpztm1Msch/Mpz+
(B6.129S7-Mpztm1Msch)
|
autoimmune response
|
J:59319
|
Mr1tm1Gfn/Mr1tm1Gfn
(B6.129P2-Mr1tm1Gfn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
Mt1tm1Bri/Mt1tm1Bri Mt2tm1Bri/Mt2tm1Bri
(involves: 129S7/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:103102
|
mt-Nd2m1
(ALR/Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:117602,
J:97969
|
Mta2tm1.1Yzha/Mta2tm1.1Yzha
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased anti-double stranded DNA antibody level
|
J:137101
|
increased autoantibody level
|
J:137101
|
increased susceptibility to systemic lupus erythematosus
|
J:137101
|
Mtus1Gt(RRA048)Byg/Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:212144
|
Mtv7BALB/c/Mtv7BALB/c
(involves: B10.Q * BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:27701
|
Mtv7BALB/c/Mtv7DBA/2
(involves: B10.Q * BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
Mtv7DBA/2/Mtv7DBA/2
(C.D2-Mtv7DBA/2)
|
decreased susceptibility to induced arthritis
|
J:27701
|
Muc19sld/Muc19sld
(NFS/N-Muc19sld)
|
increased susceptibility to autoimmune disorder
|
J:216958,
J:20364
|
Myd88tm1Aki/Myd88tm1Aki
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
Myd88tm1Aki/Myd88tm1Aki
(C.129P2-Myd88tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Myd88tm1Aki/Myd88tm1Aki Tanktm1Aki/Tanktm1Aki
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:151757
|
Myl3tm1a(EUCOMM)Hmgu/Myl3tm1a(EUCOMM)Hmgu Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
increased susceptibility to induced arthritis
|
J:343166
|
Nba4NZB/Nba4NZB
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96263
|
increased anti-single stranded DNA antibody level
|
J:96060
|
Nba4NZB/Nba4SWR
(involves: NZB * SWR)
|
increased anti-histone antibody level
|
J:96263
|
Nba10NZB/?
(involves: C57BL/6 * NZB * SB/Le)
|
increased anti-chromatin antibody level
|
J:95829
|
increased anti-double stranded DNA antibody level
|
J:95829
|
Nba10NZB/Nba10NZB Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZB)
|
increased anti-chromatin antibody level
|
J:134128
|
increased anti-double stranded DNA antibody level
|
J:134128
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
Nba10NZB/Nba10NZB Tlr7tm1Aki/Y X/Yaa
(B6.Cg-Nba10NZB Tlr7tm1Aki Yaa)
|
increased anti-chromatin antibody level
|
J:137656
|
Nba10NZB/Nba10NZB X/Yaa
(C57BL/6-Nba2 Yaa)
|
increased anti-chromatin antibody level
|
J:137656
|
increased anti-nuclear antigen antibody level
|
J:95829
|
increased autoantibody level
|
J:137656
|
increased susceptibility to autoimmune disorder
|
J:95829
|
Nba12NZB/Nba12NZB
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
Nba12NZB/Nba12SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96263
|
Nbwa1NZB/?
(involves: BALB/c * NZB * NZW)
|
increased anti-chromatin antibody level
|
J:88464
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased anti-single stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Nbwa2NZB/?
(involves: BALB/c * NZB * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Nbwa2NZW/?
(involves: BALB/c * NZB * NZW)
|
increased anti-double stranded DNA antibody level
|
J:88464
|
increased susceptibility to systemic lupus erythematosus
|
J:88464
|
Ncf2tm1b(EUCOMM)Wtsi/Ncf2+
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
Ncf2tm1b(EUCOMM)Wtsi/Ncf2tm1b(EUCOMM)Wtsi
(NZM2328.B6(Cg)-Ncf2tm1b(EUCOMM)Wtsi)
|
increased anti-double stranded DNA antibody level
|
J:260777
|
increased susceptibility to systemic lupus erythematosus
|
J:260777
|
Ndst2tm1Rls/Ndst2tm1Rls
(B6.Cg-Ndst2tm1Rls)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Nek7M1Btlr/Nek7M1Btlr
(C57BL/6J-Nek7M1Btlr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
Nfatc1tm1.1Fbs/Nfatc1tm1.1Fbs
(C57BL/6-Nfatc1tm1.1Fbs)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:305649
|
Nfatc1tm1Rao/Nfatc1tm1Rao Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:177319
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
|
increased anti-double stranded DNA antibody level
|
J:104016
|
increased anti-nuclear antigen antibody level
|
J:104016
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * C57BL/6)
|
increased susceptibility to experimental autoimmune uveoretinitis
|
J:150597
|
Nfe2l2tm1Ywk/Nfe2l2tm1Ywk
(B6.129X1-Nfe2l2tm1Ywk)
|
increased anti-double stranded DNA antibody level
|
J:165602
|
Nfil3tm1.1Kubo/Nfil3tm1.1Kubo
(B6.Cg-Nfil3tm1.1Kubo)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172134
|
Nfkb1tm1Bal/Nfkb1tm1Bal
(B6;129P-Nfkb1tm1Bal/J)
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
Nfkb2Lym1/Nfkb2Lym1
(involves: BALB/c)
|
autoimmune response
|
J:154812
|
Nfkbiatm1.1Pjc/Nfkbiatm1.1Pjc
(involves: C57BL/6)
|
autoimmune response
|
J:163686
|
increased anti-insulin autoantibody level
|
J:163686
|
increased anti-nuclear antigen antibody level
|
J:163686
|
Nfkbibtm1Bal/Nfkbibtm1Bal
(B6.129S1-Nfkbibtm1Bal)
|
decreased susceptibility to induced arthritis
|
J:163302
|
Ngfrtm1Jae/Ngfrtm1Jae
(B6.129S4-Ngfrtm1Jae)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:112769
|
Ninj1tm1Gto/Ninj1+
(B6.129P2-Ninj1tm1Gto)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
Ninj1tm1Gto/Ninj1tm1Gto
(B6.129P2-Ninj1tm1Gto)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:209516
|
Nlrp3M6Btlr/Nlrp3M6Btlr
(C57BL/6J-Nlrp3M6Btlr)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226677
|
Nlrp3tm1Wstr/Nlrp3+
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:150053
|
Nlrp3tm2Hhf/Nlrp3tm2Hhf Vsig4tm1Gne/Vsig4tm1Gne
(B6.Cg-Nlrp3tm2Hhf Vsig4tm1Gne)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
Nlrp10tm1Seis/Nlrp10tm1Seis
(B6.Cg-Nlrp10tm1Seis)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:183989
|
Nod2tm1Flv/Nod2tm1Flv
(C.129S1-Nod2tm1Flv)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Nos2tm1Mrl/Nos2tm1Mrl
(involves: 129S7/SvEvBrd * PL/J)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:46192
|
Nr3c1tm2.1Gsc/Nr3c1+
(B6.129P2-Nr3c1tm2.1Gsc)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
Nr3c1tm2Gsc/Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm/0
(B6.Cg-Nr3c1tm2Gsc Tg(Lck-cre)I57Jxm)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:137157
|
Nrrostm1Lex/Nrrostm1Lex
(B6.129S5-Nrrostm1Lex)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209569
|
Nudt7em1Ejj/Nudt7em1Ejj
(involves: C57BL/6N)
|
increased susceptibility to induced arthritis
|
J:266261
|
Nwa2NZW/LacJ/Nwa2NZW/LacJ
(involves: BALB/cJ * NZW/LacJ)
|
increased anti-histone antibody level
|
J:35434
|
increased anti-single stranded DNA antibody level
|
J:35434
|
Otub1tm1c(EUCOMM)Hmgu/Otub1tm1c(EUCOMM)Hmgu Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:280549
|
increased anti-nuclear antigen antibody level
|
J:280549
|
increased susceptibility to autoimmune disorder
|
J:280549
|
increased susceptibility to systemic lupus erythematosus
|
J:280549
|
Paam1MRL/MpJ/Paam1MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
Paam2MRL/MpJ/Paam2MRL/MpJ
(involves: C3H/HeJ * MRL/MpJ)
|
increased susceptibility to autoimmune disorder
|
J:76107
|
Padi2tm1Lex/Padi2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
autoimmune response
|
J:190651
|
Panx3tm1c(KOMP)Wtsi/Panx3tm1c(KOMP)Wtsi Tg(Col2a1-cre)1Star/0
(involves: C3H * C57BL/6 * C57BL/6J * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
Panx3tm1d(KOMP)Wtsi/Panx3tm1d(KOMP)Wtsi
(involves: BALB/cJ * C3H * C57BL/6 * C57BL/6N)
|
decreased susceptibility to induced arthritis
|
J:233542
|
Pbat1BXSB/Slc/Pbat1BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat1BXSB/Slc/Pbat1NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat2BXSB/Slc/Pbat2BXSB/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pbat2BXSB/Slc/Pbat2NZW/Slc
(involves: BXSB/Slc * NZW/Slc)
|
increased autoantibody level
|
J:49899
|
Pdcd1tm1.1Shr/Pdcd1tm1.1Shr Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:153040
|
Pdcd1tm1Hon/Pdcd1tm1Hon
(C.129S2(B6)-Pdcd1tm1Hon)
|
increased autoantibody level
|
J:66979
|
Pdcd1tm1Hon/Pdcd1tm1Hon Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:140751
|
Pdcd1tm1Hon/Pdcd1tm1Hon Vsirtm1Lex/Vsirtm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S2/SvPas * 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
Pdcd1tm1Llc/Pdcd1tm1Llc
(involves: 129S5/SvEvBrd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:126829
|
Pdcd1lg2tm3Shr/Pdcd1lg2tm3Shr
(involves: C57BL/6 * NOD/MrkTac)
|
increased susceptibility to autoimmune diabetes
|
J:123785
|
Pdcd4tm1Yhcn/Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
|
decreased susceptibility to autoimmune diabetes
|
J:120583
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:120583
|
Pecam1tm1Mak/Pecam1+
(D1.129P2-Pecam1tm1Mak)
|
increased susceptibility to induced arthritis
|
J:106275
|
Pecam1tm1Mak/Pecam1tm1Mak
(D1.129P2-Pecam1tm1Mak)
|
increased susceptibility to induced arthritis
|
J:106275
|
Pgam1tm1.1Hiko/Pgam1tm1.1Hiko Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:293746
|
Pgap3tm1.1Ymra/Pgap3tm1.1Ymra
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:181221
|
Pgap3tm1.1Ymra/Pgap3tm1.1Ymra
(B6.Cg-Pgap3tm1.1Ymra)
|
increased anti-double stranded DNA antibody level
|
J:203443
|
increased anti-single stranded DNA antibody level
|
J:203443
|
Pgia1BALB/cCrl/Pgia1DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
increased susceptibility to autoimmune disorder
|
J:66460
|
Pgia2BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia3DBA/2Crl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia4BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia6BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia7BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia8DBA/2/Pgia8DBA/2
(C.D2-(D15Mit12-D15Mit267))
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia8DBA/2/Pgia8DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia9DBA/2/Pgia9DBA/2
(C.D2-(D15Mit267-D15Mit41))
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia9DBA/2/Pgia9DBA/2
(involves: BALB/c * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:137478
|
Pgia10BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia11BALB/cCrl/?
(involves: BALB/cCrl * DBA/2Crl)
|
increased autoantibody level
|
J:66460
|
Pgia13C3H/HeJCr/Pgia13C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia14C3H/HeJCr/Pgia14C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia15C3H/HeJCr/Pgia15C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:65424
|
Pgia16C3H/HeJCr/Pgia16C3H/HeJCr
(involves: C3H/HeJCr * C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:65424
|
Pgia39DBA/2Crl/Pgia39DBA/2Crl Pgia6DBA/2Crl/Pgia6DBA/2Crl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
Pgia39DBA/2Crl/Pgia39DBA/2Crl Pgia26BALB/cCrl/Pgia26BALB/cCrl
(involves: BALB/cCrl * DBA/2Crl)
|
increased susceptibility to induced arthritis
|
J:84150
|
Pgis1DBA/2/Pgis1DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis1DBA/2/Pgis1DBA/2 Pgis2BALB/c/Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis1DBA/2/Pgis1DBA/2 Pgis2BALB/c/Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis2BALB/c/Pgis2BALB/c
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pgis2BALB/c/Pgis2DBA/2
(involves: BALB/c * DBA/2)
|
increased susceptibility to induced arthritis
|
J:107496
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz
(C.129S-Pglyrp1tm1Rdz)
|
increased susceptibility to induced arthritis
|
J:178054
|
Pglyrp1tm1Rdz/Pglyrp1tm1Rdz Pglyrp2tm1Rdz/Pglyrp2tm1Rdz
(C.129S-Pglyrp1tm1Rdz Pglyrp2tm1Rdz)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Pglyrp2tm1Rdz/Pglyrp2tm1Rdz
(C.129S-Pglyrp2tm1Rdz)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Pik3c2aGt(OST288105)Lex/Pik3c2aGt(OST288105)Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:169710
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr
(B6.129S4-Pik3cdtm1Tnr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
Pik3cdtm1Tnr/Pik3cdtm1Tnr Pik3cgtm1Pngr/Pik3cgtm1Pngr
(B6.129-Pik3cdtm1Tnr Pik3cgtm1Pngr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
Pik3cgtm1Pngr/Pik3cgtm1Pngr
(B6.129P2-Pik3cgtm1Pngr)
|
decreased susceptibility to induced arthritis
|
J:134324
|
Pkn1tm1Kik/Pkn1tm1Kik
(B6.129P2-Pkn1tm1Kik)
|
increased anti-double stranded DNA antibody level
|
J:193187
|
Pla1aem1Appsc/Pla1aem1Appsc
(C57BL/6J-Pla1aem1Appsc)
|
decreased susceptibility to induced arthritis
|
J:333902
|
Pla2g4atm1Tksh/Pla2g4atm1Tksh
(B6.129P2-Pla2g4atm1Tksh)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:107430
|
Plautm1Mlg/Plautm1Mlg
(B6.Cg-Plautm1Mlg)
|
decreased susceptibility to induced arthritis
|
J:75303
|
Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi/0
(either: B6.Cg-Plcg1tm1Gcrp/Plcg1tm1Rwen Tg(Cd4-cre)1Cwi or (involves: 129X1/SvJ * C57BL/6 * DBA/2))
|
increased anti-double stranded DNA antibody level
|
J:157757
|
Plcg2tm1Jni/Plcg2tm1Jni
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:157619
|
Plcl2tm1Tta/Plcl2tm1Tta
(involves: 129P2/OlaHsd)
|
increased anti-nuclear antigen antibody level
|
J:85960
|
Pld4thss/Pld4thss
(BALB/cJ-Pld4thss/GrsrJ)
|
increased anti-nuclear antigen antibody level
|
J:278304
|
plt/plt
(either: B6.DDD-plt or C.DDD-plt)
|
increased susceptibility to autoimmune disorder
|
J:110910
|
Polbtm1.1Jbsw/Polb+
(involves: 129/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:206872
|
Polbtm1.1Jbsw/Polbtm1.1Jbsw
(involves: 129/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:206872
|
increased susceptibility to systemic lupus erythematosus
|
J:206872
|
Ppargtm1.1Gonz/Ppargtm1.1Gonz Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
Ppargtm1Tka/Pparg+
(involves: C57BL/6 * CBA * ICR)
|
increased susceptibility to induced arthritis
|
J:58222
|
Ppargtm2Rev/Ppargtm2Rev Tg(Cd4-cre)1Cwi/?
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:153358
|
Prdm1tm1Clme/Prdm1tm1Clme Tg(Itgax-cre)1-1Reiz/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased anti-double stranded DNA antibody level
|
J:178876
|
increased anti-nuclear antigen antibody level
|
J:178876
|
increased autoantibody level
|
J:178876
|
Prf1tm1Clrk/Prf1tm1Clrk
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Prf1tm1Clrk/Prf1tm1Clrk Tg(INS-Il10)#Sar/0
(involves: 129S7/SvEvBrd * BALB/c * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Prf1tm1Sdz/Prf1+
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
Prf1tm1Sdz/Prf1tm1Sdz
(NOD.B6-Prf1tm1Sdz)
|
decreased susceptibility to autoimmune diabetes
|
J:43468
|
Prf1tm1Sdz/Prf1tm1Sdz X/Yaa
(BXSB.B6-Prf1tm1Sdz/Dcr)
|
autoimmune response
|
J:179430
|
Prkcdtm1Kin/Prkcdtm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-chromatin antibody level
|
J:76135
|
Prkcdtm1Qxu/Prkcdtm1Qxu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:76134
|
Prkcdtm1Qxu/Prkcdtm1Qxu Tg(IghelMD4)4Ccg/0 Tg(ML5sHEL)5Ccg/0
(involves: 129P2/OlaHsd * C57BL/6)
|
autoimmune response
|
J:76134
|
Prkcitm1Rfar/Prkci+ Tg(Ckmm-cre)5Khn/?
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased susceptibility to autoimmune diabetes
|
J:123964
|
Prkcqtm1Litt/Prkcqtm1Litt
(B6.129P2-Prkcqtm1Litt)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:129421
|
Prkdcscid/Prkdcscid Tg(Ins2-Fasl)24Ach/0
(NOD.Cg-Prkdcscid Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
increased susceptibility to autoimmune diabetes
|
J:81416
|
Prkdcscid/Prkdcscid Tg(INS-Il10)#Sar/0
(NOD.Cg-Prkdcscid Tg(INS-Il10)#Sar)
|
increased susceptibility to autoimmune diabetes
|
J:66103
|
Prkdcscid/Prkdcscid Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Prkdcscid Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Psen1tm1Bdes/Psen1+ Psen2tm1Bdes/Psen2tm1Bdes
(involves: 129P2/OlaHsd)
|
autoimmune response
|
J:91235
|
increased anti-single stranded DNA antibody level
|
J:91235
|
increased susceptibility to autoimmune disorder
|
J:91235
|
Pstpip2Lupo/Pstpip2Lupo
(either: (involves: C3HeB/FeJ) or (involves: C3HeB/FeJ * C57BL/6J))
|
increased autoantibody level
|
J:125785
|
Pstpip2m1Bcs/Pstpip2m1Bcs
(involves: C57BL/6)
|
autoimmune response
|
J:196534
|
Ptger4tm1Bhk/Ptger4tm1Bhk
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
decreased susceptibility to induced arthritis
|
J:78964
|
rheumatoid arthritis
|
J:78964
|
Ptgs1tm1Unc/Ptgs1tm1Unc
(B6.129P2-Ptgs1tm1Unc)
|
decreased susceptibility to induced arthritis
|
J:110716
|
Ptgs2tm1Unc/Ptgs2tm1Unc
(B6.129P2-Ptgs2tm1Unc)
|
decreased susceptibility to induced arthritis
|
J:110716
|
Ptpn6m1Btlr/Ptpn6m1Btlr
(C57BL/6J-Ptpn6m1Btlr/Mmucd)
|
increased anti-chromatin antibody level
|
J:142845
|
Ptpn6me-v/Ptpn6me-v
(C57BL/6J-Ptpn6me-v)
|
rheumatoid arthritis
|
J:20845
|
Ptpn6me/Ptpn6me
(C57BL/6J-Ptpn6me/J)
|
autoimmune response
|
J:5579
|
Ptpn6me/Ptpn6me
(involves: C3H/HeN * C57BL/6J * NFS)
|
increased autoantibody level
|
J:30994
|
Ptpn12tm1Vei/Ptpn12tm1Vei Tg(Lck-cre)1Cwi/0
(B6.Cg-Ptpn12tm1Vei Tg(Lck-cre)1Cwi)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:163910
|
Ptpn22tm1.1Draw/Ptpn22+
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
Ptpn22tm1.1Draw/Ptpn22tm1.1Draw
(involves: 129 * C57BL/6)
|
autoimmune response
|
J:201448
|
increased anti-double stranded DNA antibody level
|
J:201448
|
increased anti-insulin autoantibody level
|
J:201448
|
Ptpn22tm2Achn/Ptpn22tm2Achn Ptprctm1Weis/Ptprctm1Weis
(B6.Cg-Ptprctm1Weis Ptpn22tm2Achn)
|
increased autoantibody level
|
J:147129
|
Ptprctm1Weis/Ptprc+
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
Ptprctm1Weis/Ptprctm1Weis
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:66501
|
increased susceptibility to autoimmune disorder
|
J:66501
|
Ptprntm1Aln/Ptprntm1Aln
(NOD.129S4-Ptprntm1Aln)
|
increased susceptibility to autoimmune diabetes
|
J:107161
|
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129 * Swiss Webster)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:79860
|
Rag1tm1Mom/Rag1tm1Mom
(involves: 129S7/SvEvBrd * C57BL/6)
|
autoimmune response
|
J:138466
|
Rag1tm1Mom/Rag1tm1Mom Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD.Cg-Rag1tm1Mom Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
Rag1tm1Mom/Rag1tm1Mom Tg(TcraBDC12-4.1)10Jos/0 Tg(TcrbBDC12-4.1)82Gse/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:111874
|
Rag1tm1Mom/Rag1tm1Mom Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
Rag2tm1.1Cgn/Rag2tm1.1Cgn Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
autoimmune response
|
J:134764
|
Rasgrp1lag/Rasgrp1lag
(involves: 129 * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:85189
|
Rasgrp1m1Anu/Rasgrp1+
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
Rasgrp1m1Anu/Rasgrp1m1Anu
(C57BL/6JSfdAnu-Rasgrp1m1Anu)
|
autoimmune response
|
J:104190
|
Rasgrp1m1Anu/Rasgrp1m1Anu
(involves: C57BL/6JSfdAnu * CBA/J)
|
increased anti-nuclear antigen antibody level
|
J:207898
|
Rasgrp1tm1.1Wz/Rasgrp1tm1.1Wz
(B6.Cg-Rasgrp1tm1.1Wz)
|
increased autoantibody level
|
J:225109
|
Rasgrp4tm1(cre)Rls/Rasgrp4tm1(cre)Rls
(C57BL/6-Rasgrp4tm1(cre)Rls)
|
decreased susceptibility to induced arthritis
|
J:186519
|
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
increased anti-double stranded DNA antibody level
|
J:168749
|
Rc3h1san/Rc3h1san
(either: C57BL/6JSfdAnu-Rc3h1san/Anu or (involves: C57BL/6JSfdAnu * CBA/Ca))
|
increased anti-double stranded DNA antibody level
|
J:98938
|
increased anti-nuclear antigen antibody level
|
J:98938
|
Reltm1Hcl/Reltm1Hcl
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:118907
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:79107
|
Rftn1tm1Ayos/Rftn1tm1Ayos
(B6.Cg-Rftn1tm1Ayos)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
Rnaseh2bem1Anu/Rnaseh2b+ Tlr7em2Anu/Tlr7+
(C57BL/6NCrl-Rnaseh2bem1Anu Tlr7em2Anu)
|
increased autoantibody level
|
J:324448
|
Rnf128tm1Cdon/Rnf128+
(involves: 129 * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
Rnf128tm1Cdon/Rnf128tm1Cdon
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:160681
|
Rnf128tm1Cdon/Rnf128tm1Cdon
(involves: 129 * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:160681
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:160681
|
Ro60tm1Woln/Ro60+
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:84627
|
Ro60tm1Woln/Ro60tm1Woln
(involves: 129S1/Sv * C57BL/6)
|
increased anti-chromatin antibody level
|
J:84627
|
increased anti-double stranded DNA antibody level
|
J:84627
|
increased anti-histone antibody level
|
J:84627
|
increased anti-nuclear antigen antibody level
|
J:84627
|
increased anti-single stranded DNA antibody level
|
J:84627
|
Rorctm1.1Zsun/Rorctm1.1Zsun
(B6(129S4)-Rorctm1.1Zsun)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
Rorctm1Litt/Rorctm1Litt
(involves: 129P2/OlaHsd)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:248565
|
Rpl13atm1.1Jesc/Rpl13atm1.1Jesc
(NOD.129S5(Cg)-Rpl13atm1.1Jesc)
|
decreased susceptibility to autoimmune diabetes
|
J:237822
|
Rr17tm1.1Cdon/Rr17tm1.1Cdon
(involves: 129S6/SvEvTac * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:181186
|
Rragcem1Efe/Rragc+ Tg(Vav-BCL2)69Jad/0
(Not Specified)
|
decreased susceptibility to autoimmune disorder
|
J:320567
|
Rubcnem1Dgre/Rubcnem1Dgre
(involves: C57BL/6 * C57BL/6N)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased anti-nuclear antigen antibody level
|
J:235399
|
increased autoantibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Rxratm1Krc/Rxratm1Krc Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:168799
|
increased anti-nuclear antigen antibody level
|
J:168799
|
increased anti-single stranded DNA antibody level
|
J:168799
|
increased autoantibody level
|
J:168799
|
S1pr1tm1Jch/S1pr1tm1Jch Tg(GFAP-cre)25Mes/?
(involves: C57BL/6J * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
S1pr1tm1Jch/S1pr1tm1Jch Tg(Nes-cre)1Kln/0
(involves: C57BL/6J * SJL)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:168824
|
Satb1tm2Kos/Satb1tm2Kos Commd10Tg(Vav1-icre)A2Kio/Commd10+
(involves: C57BL/6 * C57BL/10 * CBA/Ca)
|
increased anti-nuclear antigen antibody level
|
J:252606
|
increased autoantibody level
|
J:252606
|
increased susceptibility to autoimmune disorder
|
J:252606
|
Scara5tm1Ktry/Scara5tm1Ktry
(B6N.129X1-Scara5tm1Ktry)
|
increased anti-nuclear antigen antibody level
|
J:195536
|
Scarf1tm1Tkms/Scarf1tm1Tkms
(involves: C57BL/6)
|
increased anti-histone antibody level
|
J:208237
|
increased anti-nuclear antigen antibody level
|
J:208237
|
increased anti-single stranded DNA antibody level
|
J:208237
|
increased susceptibility to systemic lupus erythematosus
|
J:208237
|
Secia1DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia2DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia3FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia4DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia5DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia6DBA/1J/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia7FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Secia8FVB/NJ/?
(involves: DBA/1J * FVB/NJ)
|
increased susceptibility to induced arthritis
|
J:123131
|
Selltm1Flv/Sell+
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:88947
|
Selltm1Flv/Selltm1Flv
(involves: C57BL/6 * NOD)
|
decreased susceptibility to autoimmune disorder
|
J:88947
|
Selptm1Bay/Selptm1Bay
(D1.129S7(B6J)-Selptm1Bay)
|
increased susceptibility to induced arthritis
|
J:57086
|
Senp1tm1Wami/Senp1tm1Wami Tg(Fabp4-cre)#Abel/0
(B6.Cg-Senp1tm1Wami Tg(Fabp4-cre)#Abel)
|
increased anti-insulin autoantibody level
|
J:228009
|
increased susceptibility to autoimmune diabetes
|
J:228009
|
Shcbp1tm1c(EUCOMM)Wtsi/Shcbp1tm1c(EUCOMM)Wtsi Tg(Lck-cre)1Cwi/?
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
Shcbp1tm1d(EUCOMM)Wtsi/Shcbp1tm1d(EUCOMM)Wtsi
(involves: C57BL/6N * FVB/N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:212898
|
Siglecgtm1Lnit/Siglecgtm1Lnit
(involves: BALB/c)
|
autoimmune response
|
J:123353
|
Sirt1tm1Mcby/Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased anti-nuclear antigen antibody level
|
J:160869
|
Sirt1tm1Mcby/Sirt1tm1Mcby
(involves: 129S1/Sv * 129X1/SvJ)
|
increased autoantibody level
|
J:241633
|
Sit1tm1Lsmn/Sit1tm1Lsmn
(B6.Cg-Sit1tm1Lsmn)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:100408
|
Skap2Gt(VICTR20)21Lex/Skap2Gt(VICTR20)21Lex
(B6.129S5-Skap2Gt(VICTR20)21Lex)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:101373
|
Slamf9em1Isha/Slamf9em1Isha
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:279164
|
Slc1a5tm1Tac/Slc1a5tm1Tac
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:254980
|
Slc5a2tm1Lex/Slc5a2tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6J)
|
decreased susceptibility to autoimmune diabetes
|
J:195941
|
Sle1NZW/Sle1NZW Sles1NZW/Sles1NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:100678
|
Sle1NZW/Sle1NZW Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:134128
|
Sle1aC57BL/6J/Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1aNZM2410/J/Sle1aNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1bC57BL/6J/Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1bNZM2410/J/Sle1bNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1cC57BL/6J/Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle1cNZB/Sle1cNZM2410/J
(involves: C57BL/6J * NZB * NZM2410/J)
|
increased autoantibody level
|
J:145133
|
Sle1cNZM2410/J/Sle1cNZM2410/J
(involves: C57BL/6J * NZM2410/J)
|
increased anti-chromatin antibody level
|
J:67544
|
Sle6NZW/Sle6NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sle9BXSB/J/Sle9BXSB/J
(involves: BXSB/J * C57BL/10Ola)
|
increased anti-nuclear antigen antibody level
|
J:60445
|
Sle16129S6/SvEvTac/Sle16129S6/SvEvTac
(B6.129-Sle16129S6/SvEvTac)
|
increased autoantibody level
|
J:122132
|
increased susceptibility to systemic lupus erythematosus
|
J:122132
|
Sles1C57BL/6/Sles1C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles1NZW/Sles1NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2C57BL/6/Sles2C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2C57BL/6/Sles2NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles2NZW/Sles2NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3C57BL/6/Sles3C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3C57BL/6/Sles3NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles3NZW/Sles3NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4C57BL/6/Sles4C57BL/6
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4C57BL/6/Sles4NZW
(involves: C57BL/6 * NZW)
|
increased susceptibility to systemic lupus erythematosus
|
J:57246
|
Sles4NZW/Sles4NZW
(involves: C57BL/6 * NZW)
|
decreased susceptibility to systemic lupus erythematosus
|
J:57246
|
Slfn8tm1Aki/Slfn8tm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:258797
|
Smad7tm1.1Ink/Smad7tm1.1Ink Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * DBA/2)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
Socs1tm1.1Ayr/Socs1tm1.1Ayr
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:226678
|
Socs1tm1Ayos/Socs1tm1Ayos Tg(Lck-cre)1Jtak/0
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
Socs3tm1Robb/Socs3tm1Robb
(involves: C57BL/6)
|
increased susceptibility to induced arthritis
|
J:145513
|
Sod3tm1Mrkl/Sod3tm1Mrkl
(D1.129P2-Sod3tm1Mrkl)
|
increased susceptibility to induced arthritis
|
J:106273
|
Spink14tm1e(KOMP)Wtsi/Spink14tm1e(KOMP)Wtsi
(C57BL/6N-Spink14tm1e(KOMP)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Spntm1Bam/Spntm1Bam
(B6;129S4-Spntm1Bam/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:86932
|
Spp1tm1Blh/Spp1tm1Blh
(B6.129S6-Spp1tm1Blh)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:116272
|
St14tm2Bug/St14tm3Bug Tg(MMTV-cre)4Mam/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * FVB/NJ * N:Black Swiss)
|
increased anti-nuclear antigen antibody level
|
J:213072
|
increased autoantibody level
|
J:213072
|
Stat4tm1Gru/Stat4tm1Gru
(NOD.129S2-Stat4tm1Gru)
|
decreased susceptibility to autoimmune diabetes
|
J:90600
|
Stat4tm1Gru/Stat4tm1Gru Tg(Ins2-GP)34-20Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
abnormal susceptibility to autoimmune disorder
|
J:107047
|
Stat4tm1Gru/Stat4tm1Gru Tg(Ins2-NP)25-3Olds/0
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:107047
|
Stat4tm1Jni/Stat4tm1Jni
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
Stat4tm1Jni/Stat4tm1Jni Stat6tm1Jni/Stat6tm1Jni
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:96338
|
Stat6tm1Jni/Stat6tm1Jni
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:96338
|
Stim1tm1Kuro/Stim1tm1Kuro Stim2tm1.1Kuro/Stim2tm1.1Kuro Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:172608
|
Stk17btm1Hed/Stk17btm1Hed
(B6.129X1-Stk17btm1Hed)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:94685
|
Swap70tm1Jess/Swap70tm1Jess
(involves: 129T2/SvEms * 129X1/SvJ)
|
increased autoantibody level
|
J:71160
|
Swrl2SWR/Swrl2SWR
(involves: NZB * SWR)
|
increased anti-single stranded DNA antibody level
|
J:96060
|
Swrl3NZB/Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
Swrl3SWR/Swrl3SWR
(involves: NZB * SWR)
|
increased anti-double stranded DNA antibody level
|
J:96060
|
increased anti-histone antibody level
|
J:96060
|
increased anti-nuclear antigen antibody level
|
J:73097
|
Syktm2.1(ZAP70)Fkfr/Syktm2.1(ZAP70)Fkfr
(B6.129-Syktm2.1(ZAP70)Fkfr)
|
increased anti-insulin autoantibody level
|
J:188422
|
Syt7tm1Nan/Syt7tm1Nan
(involves: 129S1/Sv * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:85201
|
increased susceptibility to autoimmune disorder
|
J:85201
|
Syvn1tm1Tn/Syvn1+
(D1.Cg-Syvn1tm1Tn)
|
decreased susceptibility to induced arthritis
|
J:86009
|
Tanktm1Aki/Tanktm1Aki
(involves: 129/Sv * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:151757
|
increased anti-nuclear antigen antibody level
|
J:151757
|
Tap1tm1Arp/Tap1tm1Arp X/Yaa
(BXSB.129S2(B6)-Tap1tm1Arp/Dcr)
|
increased susceptibility to systemic lupus erythematosus
|
J:179430
|
Tarm1tm1Yiw/Tarm1tm1Yiw
(involves: C57BL/6 * C57BL/6NSlc)
|
decreased susceptibility to induced arthritis
|
J:301164
|
Tbc1d10ctm1.1Psou/Tbc1d10ctm1.2Psou Cd79atm1(cre)Reth/Cd79a+
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
Tbc1d10ctm1.2Psou/Tbc1d10ctm1.2Psou
(involves: 129S2/SvPas * C57BL/6J)
|
increased anti-double stranded DNA antibody level
|
J:211913
|
increased susceptibility to systemic lupus erythematosus
|
J:211913
|
Tbk1tm1Arte/Tbk1tm1Arte Cd19tm1(cre)Cgn/Cd19+
(involves: 129/SvEv * 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:188560
|
increased anti-nuclear antigen antibody level
|
J:188560
|
Tbx21tm1Glm/Tbx21tm1Glm
(C.129S6-Tbx21tm1Glm/J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:111932
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi
(B6.129-Tcra-Jtm1Tgi)
|
decreased susceptibility to induced arthritis
|
J:99107
|
Tcratm1Mjo/Tcra+
(NOD.129P2-Tcratm1Mjo)
|
decreased susceptibility to autoimmune diabetes
|
J:108590
|
Tcratm1Mjo/Tcratm1Mjo
(involves: 129P2/OlaHsd * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:111129
|
increased anti-nuclear antigen antibody level
|
J:111129
|
increased autoantibody level
|
J:111129
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom
(B6.129P2-Tcrbtm1Mom Tcrdtm1Mom/J)
|
decreased autoantibody level
|
J:187766
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg/Igh-J+
(B6.129P2-Tcrbtm1Mom Igh-Jtm2(3H9-VDJ*)Mwg Tcrdtm1Mom)
|
increased anti-double stranded DNA antibody level
|
J:142389
|
Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(B6.129-Tcrbtm1Mom Traf3ip2tm1.1Lix Tcrdtm1Mom)
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
Tet1tm1.2Jae/Tet1tm1.2Jae Tet2tm1.1Iaai/Tet2tm1.1Iaai Tet3tm1.1Yzhg/Tet3tm1.1Yzhg Tg(Rorc-cre)1Litt/0
(involves: 129 * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB)
|
increased susceptibility to autoimmune disorder
|
J:333574
|
Tg(ACTB-TNFRSF6B)754Jwu/?
(B6.Cg-Tg(Actb-TNFRSF6B)754Jwu)
|
increased anti-double stranded DNA antibody level
|
J:148162
|
increased autoantibody level
|
J:148162
|
Tg(BCL2)22Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased susceptibility to autoimmune disorder
|
J:93111
|
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased susceptibility to autoimmune disorder
|
J:93111
|
Tg(CAG-C1qtnf6)#Yiw/0
(involves: C57BL/6JJcl)
|
decreased susceptibility to induced arthritis
|
J:227217
|
Tg(CAG-p35)1Miur/0
(involves: C57BL/6)
|
autoimmune response
|
J:126593
|
Tg(CAG-p35)1Miur/0 Tg(Mbp-cre)29Miur/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:126593
|
Tg(CAG-SYVN1)1Tn/?
(D1.Cg-Tg(CAG-SYVN1)1Tn)
|
rheumatoid arthritis
|
J:86009
|
Tg(CD2-Lrch1)#Liux/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238772
|
Tg(CD2-Rorc)#Staka/0
(involves: C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:230700
|
increased autoantibody level
|
J:230700
|
increased susceptibility to autoimmune disorder
|
J:230700
|
Tg(Cd2-Smad7)#Chbe/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:184670
|
Tg(Cd4-BCL2*G101A*D102A*D103A)AWnt/0
(involves: C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:217939
|
increased autoantibody level
|
J:217939
|
increased susceptibility to autoimmune disorder
|
J:217939
|
Tg(Cd4-CD4)2362Litt/0 Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2 * SJL)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
Tg(Cd4-DsRed)4Lt/0
(NOD/ShiLt-Tg(Cd4-DsRed)4Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:127785
|
Tg(CD4-Il17re)#Cdon/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177650
|
Tg(Cd4-TGFBR2)16Flv/?
(involves: C3H * C57BL/6 * C57BL/10 * C57BR/cd)
|
increased anti-nuclear antigen antibody level
|
J:97554
|
Tg(Cd152Ig)1Jbs/0
(involves: C3H * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:35353
|
Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-H2-K1)#Papl/0
(B6.Cg-Tg(CKMM-tTA)A3Rhvh Tg(tetO-H2-K1)#Papl)
|
increased anti-nuclear antigen antibody level
|
J:205907
|
increased autoantibody level
|
J:205907
|
Tg(Col2a1-Mir140)#Asah/0
(C57BL/6-Tg(Col2a1-Mir140)#Asah)
|
decreased susceptibility to induced arthritis
|
J:160358
|
Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
|
increased autoantibody level
|
J:117018
|
increased susceptibility to autoimmune disorder
|
J:117018,
J:145185
|
Tg(FCGR2A)11Mkz/Tg(FCGR2A)11Mkz
(involves: C57BL/6 * SJL)
|
increased anti-histone antibody level
|
J:136516
|
increased susceptibility to induced arthritis
|
J:136516
|
Tg(H2-Ea-G6pc2)69Tkay/?
(NOD-Tg(H2-Ea-G6pc2)69Tkay)
|
increased anti-insulin autoantibody level
|
J:117352
|
increased susceptibility to autoimmune diabetes
|
J:117352
|
Tg(H2-Ea-Ins2)1Wehi/Tg(H2-Ea-Ins2)1Wehi
(NOD/ShiLtJWehi-Tg(H2-Ea-Ins2)1Wehi)
|
decreased anti-insulin autoantibody level
|
J:117352
|
Tg(H2-Ead)5Lt/0
(NOD/ShiLt-Tg(H2-Ead)5Lt)
|
autoimmune response
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
Tg(H2-Ead)12Lt/0
(NOD/ShiLt-Tg(H2-Ead)12Lt)
|
autoimmune response
|
J:36435
|
decreased susceptibility to autoimmune diabetes
|
J:36435
|
Tg(H2-K-MC159/EGFP)13Fkmc/Tg(H2-K-MC159/EGFP)13Fkmc
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:138050
|
Tg(H2-Kb-Tcra,-Tcrb)1640Kurs/0
(SJL.FVB-Tg(H2-Kb-Tcra,-Tcrb)1640Kurs)
|
increased autoantibody level
|
J:149511
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149511
|
Tg(HLA-A/H2-D/B2M)1Dvs/0
(NOD/ShiLtDvs-Tg(HLA-A/H2-D/B2M)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:121685
|
Tg(HLA-B27)30-4Trg/?
(involves: C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:109851
|
Tg(HLA-DQA1,HLA-DQB1)1Dv/0 Tg(Ins2-CD80)3B7Flv/0
(B6.Cg-Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(Ins2-CD80)3B7Flv)
|
decreased susceptibility to autoimmune diabetes
|
J:59245
|
Tg(HLA-DR2)#Lfug/0 Tg(TCROb.1A12)#Lfug/0
(involves: C57BL/6 * DBA/2)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:134764
|
Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz/Tg(HLA-DRA*0101,HLA-DRB1*0101)1Dmz
(involves: C57BL/6 * C57BL/10Sn * SJL/J)
|
increased autoantibody level
|
J:108635
|
increased susceptibility to induced arthritis
|
J:108635
|
Tg(Igh3H9)41Mwg/?
(involves: C57BL/6 * SJL)
|
increased anti-single stranded DNA antibody level
|
J:119625
|
Tg(Igh-6-Cd80)1Gjf/0
(NOD.FVB-Tg(Igh-6-Cd80)1Gjf/JbsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:131077
|
Tg(Igh-6/Igh-V125)2Jwt/0 Tg(Igk-C/Igk-V125)1Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V125)2Jwt Tg(Igk-C/Igk-V125)1Jwt)
|
increased susceptibility to autoimmune diabetes
|
J:91865
|
Tg(Igh-6/Igh-V281)3Jwt/0
(NOD.B6-Tg(Igh-6/Igh-V281)3Jwt)
|
decreased susceptibility to autoimmune diabetes
|
J:91865
|
Tg(Igh-V-CD40lg)#Tsub/0
(C57BL/6-Tg(Igh-V-CD40lg)#Tsub)
|
increased anti-double stranded DNA antibody level
|
J:128824
|
increased anti-histone antibody level
|
J:128824
|
increased anti-single stranded DNA antibody level
|
J:128824
|
Tg(Igh-V-CD40lg)#Tsub/0
(involves: C57BL/6)
|
increased autoantibody level
|
J:89855
|
Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.B6-Tg(IghelMD4)4Ccg/DvsJ)
|
increased susceptibility to autoimmune diabetes
|
J:80859
|
Tg(IghH280)48Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
Tg(IghH280)48Dvs/? Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IghH280)48Dvs Tg(IgkH280)934Dvs/Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
Tg(Ighm-Ctla4Ig/Cd80)1Jbs/0
(NOD.FVB-Tg(Ighm-Ctla4Ig/Cd80)1Jbs)
|
decreased susceptibility to autoimmune diabetes
|
J:113109
|
Tg(IgkH280)934Dvs/?
(NOD/ShiLtDvs-Tg(IgkH280)934Dvs/J)
|
increased susceptibility to autoimmune diabetes
|
J:274578
|
Tg(Ins1-Cat,Tyr)25Pne/0
(NOD.FVB-Tg(Ins1-Cat,Tyr)25Pne)
|
increased susceptibility to autoimmune diabetes
|
J:108415
|
Tg(Ins1-EGFP/GH1)14Hara/0
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
Tg(Ins1-EGFP/GH1)14Hara/Tg(Ins1-EGFP/GH1)14Hara
(NOD/ShiLtJ-Tg(Ins1-EGFP/GH1)14Hara)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
Tg(Ins2*Y16A)1Ell/0
(NOD-Tg(Ins2*Y16A)1Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Tg(Ins2*Y16A)3Ell/0
(NOD-Tg(Ins2*Y16A)3Ell)
|
increased susceptibility to autoimmune diabetes
|
J:98583
|
Tg(Ins2-CD80)3B7Flv/?
(involves: C57BL/6 * CBA/Ca * NOD/Caj)
|
increased susceptibility to autoimmune diabetes
|
J:26618
|
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-CD80)3B7Flv/0 Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0
(involves: C57BL/6 * CBA/Ca)
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * CBA/Ca * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-CD86)12B70Flv/0 Tg(Ins2-Tnf)17Flv/0
(involves: C57BL/6 * CBA/Ca)
|
increased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-Cd274)2Mdos/?
(NOD/ShiLt-Tg(Ins2-Cd274)2Mdos)
|
increased susceptibility to autoimmune diabetes
|
J:118934
|
Tg(Ins2-cre)5Lt/0
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
increased susceptibility to autoimmune diabetes
|
J:127015
|
Tg(Ins2-cre)5Lt/Tg(Ins2-cre)5Lt
(NOD/ShiLt-Tg(Ins2-cre)5Lt)
|
decreased susceptibility to autoimmune disorder
|
J:127015
|
Tg(Ins2-crmA)27Ngkh/?
(NOD-Tg(Ins2-CrmA)27Ngkh)
|
increased susceptibility to autoimmune diabetes
|
J:132052
|
Tg(Ins2-E3)1Dvs/?
(NOD.Cg-Tg(Ins2-E3)1Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:68996
|
Tg(Ins2-E3*309)5Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*309)5Dvs/Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
Tg(Ins2-E3*704)2Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*704)2Dvs)
|
decreased susceptibility to autoimmune diabetes
|
J:83195
|
Tg(Ins2-E3*734)3Dvs/0
(NOD/ShiLtDvs-Tg(Ins2-E3*734)3Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
Tg(Ins2-E3*734)4Dvs/?
(NOD/ShiLtDvs-Tg(Ins2-E3*734)4Dvs/DvsJ)
|
decreased susceptibility to autoimmune diabetes
|
J:106340
|
Tg(Ins2-Fas*I246N)1Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Tg(Ins2-Fas*I246N)1Ach/0 Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fas*I246N)1Ach Tg(Ins2-Fasl)24Ach)
|
decreased susceptibility to autoimmune diabetes
|
J:81416
|
Tg(Ins2-Fasl)24Ach/0
(NOD-Tg(Ins2-Fasl)24Ach/J)
|
increased susceptibility to autoimmune diabetes
|
J:78679,
J:81416
|
Tg(Ins2-GAD2)2Lt/0
(NOD/ShiLt-Tg(Ins2-GAD2)2Lt)
|
decreased susceptibility to autoimmune diabetes
|
J:100251
|
Tg(Ins2-GP)34-20Olds/0
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
Tg(Ins2-H2-Ead,Ins2-H2-Eb1b)187-7Bri/0
(involves: C57BL/6 * SJL)
|
decreased susceptibility to autoimmune diabetes
|
J:93555
|
Tg(Ins2-Iapp)6Soel/Tg(Ins2-Iapp)6Soel
(involves: FVB/N)
|
decreased susceptibility to autoimmune diabetes
|
J:130022
|
Tg(Ins2-IAPP)RHFSoel/Tg(Ins2-IAPP)RHFSoel
(involves: FVB/N)
|
increased susceptibility to autoimmune diabetes
|
J:130022
|
Tg(Ins2-NP)25-3Olds/0
(involves: BALB/c * C57BL/6)
|
decreased susceptibility to autoimmune diabetes
|
J:81287
|
increased susceptibility to autoimmune diabetes
|
J:81287
|
Tg(Ins2-OVA)59Wehi/?
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
Tg(Ins2-OVA)307Wehi/?
(involves: BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:99560
|
Tg(Ins2-OVA)307Wehi/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * C57BL/6JWehi)
|
autoimmune response
|
J:99451
|
Tg(Ins2-TFRC/OVA)296Wehi/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:122114
|
Tg(INS-Il10)#Sar/0 Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
Tg(INS-Il10)#Sar/0 Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
increased susceptibility to autoimmune diabetes
|
J:64051
|
Tg(KRT5-rtTA)1Glk/0 Tg(tetO/CMV-Tslp)#Sfz/0
(C.Cg-Tg(KRT5-rtTA)1Glk Tg(tetO/CMV-Tslp)#Sfz)
|
increased autoantibody level
|
J:182756
|
increased susceptibility to autoimmune hemolytic anemia
|
J:182756
|
Tg(Lck-Socs3)1Kubo/0
(Not Specified)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:132905
|
Tg(Lck-Stk17b)26.1Wals/?
(B6.Cg-Tg(Lck-Stk17b)26.1Wals)
|
increased anti-nuclear antigen antibody level
|
J:149973
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:149973
|
Tg(Lck-Tnfsf14)24Yxf/?
(C57BL/6-Tg(Lck-Tnfsf14)24Yxf)
|
increased anti-double stranded DNA antibody level
|
J:129951
|
increased anti-nuclear antigen antibody level
|
J:128976
|
increased autoantibody level
|
J:129951
|
Tg(Lck-Tslp)1Chea/0
(B6.Cg-Tg(Lck-Tslp)1Chea)
|
increased anti-nuclear antigen antibody level
|
J:72982
|
Tg(Lck/Emu-Rftn1)1Ayos/?
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:150299
|
Tg(Mir125a)#Smoc/0
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:224880
|
Tg(Plp1-Eif2ak3*)18Pop/0
(C57BL/6J-Tg(Plp1-Eif2ak3*)18Pop)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:238042
|
Tg(Psp-Rbbp4)1Yoha/0
(involves: C57BL/6)
|
increased autoantibody level
|
J:141378
|
increased susceptibility to autoimmune disorder
|
J:141378
|
Tg(SV40-Igh-64C8)H3Hon/0 Tg(SV40-Igk4C8)L1Hon/0
(involves: C57BL/6)
|
increased anti-erythrocyte antigen antibody level
|
J:139864
|
Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
increased susceptibility to autoimmune disorder
|
J:83278
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:83278
|
Tg(Tcra,Tcrb)24Efro/0
(D1.Cg-Tg(Tcra,Tcrb)24Efro)
|
autoimmune response
|
J:104243
|
increased autoantibody level
|
J:104243
|
increased susceptibility to autoimmune disorder
|
J:104243
|
Tg(TcraAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:93553
|
Tg(TcraAI4)1Dvs/0 Tg(TcrbAI4)1Dvs/0
(NOD-Tg(TcraAI4)1Dvs Tg(TcrbAI4)1Dvs)
|
increased susceptibility to autoimmune diabetes
|
J:94192
|
Tg(TcraAV19AJ33)1Shima/?
(involves: 129S4/SvJae * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:112657
|
Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(NOD.Cg-Tg(TcraBDC2.5,TcrbBDC2.5)1Doi)
|
decreased susceptibility to autoimmune diabetes
|
J:87251
|
Tg(TcraR28,TcrbR28)KRNDim/0
(involves: C57BL/6 * NOD * SJL)
|
rheumatoid arthritis
|
J:36815
|
Tg(TcraTcrbNY4.1)1Pesa/0
(NOD.Cg-Tg(TcraTcrbNY4.1)1Pesa)
|
increased susceptibility to autoimmune diabetes
|
J:108768
|
Tg(TcrbBL17)1Lmor/0
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Tg(TcrbBL17)1Lmor/Tg(TcrbBL17)1Lmor
(involves: DBA/1J * SWR/J)
|
increased susceptibility to induced arthritis
|
J:134111
|
Tg(TcrLCMV)327Sdz/Tg(TcrLCMV)327Sdz
(NOD.Cg-Tg(TcrLCMV)327Sdz/Dvs)
|
autoimmune response
|
J:71050
|
Tg(tetO-MAP2K1)#Ahsa/? Tg(CD2-rtTA)CRza/?
(involves: C57BL/6 * C57BL/10 * CBA * SJL)
|
increased anti-double stranded DNA antibody level
|
J:174339
|
Tg(Tlr7)1Boll/0
(involves: C57BL/6)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
X/Tg(Tlr7)6Boll
(involves: C57BL/6)
|
autoimmune response
|
J:127600
|
increased anti-nuclear antigen antibody level
|
J:127600
|
Tg(Tnfsf13b)1Fma/0
(involves: C57BL/6 * DBA/2J)
|
increased anti-double stranded DNA antibody level
|
J:58798
|
increased anti-single stranded DNA antibody level
|
J:58798
|
increased autoantibody level
|
J:58798
|
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased autoantibody level
|
J:114782
|
Tg(Tnfsf13b)1Fma/?
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased anti-double stranded DNA antibody level
|
J:113556
|
Tgfb1tm3.1Flv/Tgfb1tm3.1Flv Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Cd4-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
autoimmune response
|
J:148747
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Cd4-cre)1Cwi/0 Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * DBA/2 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tnfrsf4tm2(cre)Nik/Tnfrsf4+ Tg(TcraBDC2.5,TcrbBDC2.5)1Doi/0
(involves: 129 * C57BL/6 * NOD * SJL)
|
increased susceptibility to autoimmune diabetes
|
J:196160
|
TgTn(pb-CAG-Gm614)#Cya/0
(involves: C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:307345
|
Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: 129S2/SvPas * C57BL/6)
|
increased anti-single stranded DNA antibody level
|
J:153126
|
Thop1Gt(CSG163)Byg/Thop1Gt(CSG163)Byg
(B6.129P2-Thop1Gt(CSG163)Byg)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:290567
|
Tigittm1Sdl/Tigittm1Sdl
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
Tigittm1Sdl/Tigittm1Sdl Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:168902
|
Timd4tm1Kuch/Timd4tm1Kuch
(C57BL/6-Timd4tm1Kuch)
|
increased anti-double stranded DNA antibody level
|
J:160747
|
Timd4tm1Kuch/Timd4tm1Kuch
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:235399
|
increased susceptibility to systemic lupus erythematosus
|
J:235399
|
Tlr4Lps-d/Tlr4Lps-d
(involves: C3H/HeJ)
|
increased susceptibility to induced arthritis
|
J:96356
|
Tlr4tm1Aki/Tlr4tm1Aki
(C.129P2-Tlr4tm1Aki)
|
decreased susceptibility to induced arthritis
|
J:178054
|
Tlr5tm1Flv/Tlr5tm1Flv
(involves: 129S1/Sv * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:158055
|
Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
Tlr7em2Anu/Tlr7+
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-double stranded DNA antibody level
|
J:324448
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased autoantibody level
|
J:324448
|
Tlr7em2Anu/Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
|
increased anti-nuclear antigen antibody level
|
J:324448
|
increased anti-single stranded DNA antibody level
|
J:324448
|
increased susceptibility to systemic lupus erythematosus
|
J:324448
|
Tlr7tm1Flv/Tlr7tm1Flv
(B6.129S1-Tlr7tm1Flv)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr7+ Tlr8/Tlr7tm1Vlcg/Tlr8tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8/Tlr7tm1Vlcg/Tlr8/Tlr7tm1Vlcg
(B6.Cg-Tlr8/Tlr7tm1Vlcg Tlr8tm1Vlcg)
|
decreased anti-insulin autoantibody level
|
J:165267
|
Tlr8tm1Vlcg/Tlr8tm1Vlcg
(B6.129S1-Tlr8tm1Vlcg)
|
increased anti-double stranded DNA antibody level
|
J:165267
|
increased anti-nuclear antigen antibody level
|
J:165267
|
Tlr9tm1Aki/Tlr9tm1Aki
(B6.129P2-Tlr9tm1Aki)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:105435
|
Tmem178tm1Lex/Tmem178tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to induced arthritis
|
J:228311
|
TnfBpsm1/Tnf+
(involves: C57BL/6)
|
rheumatoid arthritis
|
J:226052
|
TnfBpsm1/TnfBpsm1
(involves: C57BL/6)
|
rheumatoid arthritis
|
J:226052
|
Tnftm1.1Sned/Tnftm1.1Sned Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
Tnftm1.1Sned/Tnftm1.1Sned Tg(Cd4-cre)1Cwi/0
(involves: 129 * C57BL/6 * DBA/2)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
Tnftm1Gkl/Tnftm1Gkl
(involves: 129S/SvEv)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
Tnftm1Gkl/Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
Tnftm1Jods/Tnftm1Jods
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:44545,
J:98591
|
Tnftm1Jods/Tnftm1Jods
(C57BL/6-Tnftm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:118417
|
Tnftm1Jods/Tnftm1Jods
(C57BL/6-Ltatm1Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:47428
|
Tnftm1Ljo/Tnftm1Ljo
(involves: 129S1/Sv)
|
decreased susceptibility to autoimmune disorder
|
J:95684
|
Tnftm2Gkl/Tnf+
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
Tnftm2Gkl/Tnf+ Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
Tnftm2Gkl/Tnftm2Gkl
(involves: 129S/SvEv * C57BL/6)
|
rheumatoid arthritis
|
J:54056
|
Tnftm2Jods/Tnftm2Jods
(C57BL/6-Tnftm2Jods)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:98591
|
Tnftm3Gkl/Tnftm3Gkl
(involves: 129S/SvEv * C57BL/6)
|
autoimmune response
|
J:114740
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:114740
|
Tnfaip3tm2Ama/Tnfaip3tm2Ama Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased autoantibody level
|
J:163917
|
increased susceptibility to autoimmune disorder
|
J:163917
|
Tnfrsf1atm1.1Gkl/Tnfrsf1atm1.1Gkl
(involves: 129/Sv * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:92470
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
Tnfrsf1atm1Blt/Tnfrsf1atm1Blt Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
decreased susceptibility to experimental autoimmune uveoretinitis
|
J:115094
|
decreased susceptibility to induced arthritis
|
J:120707
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Tnfrsf1atm1Mak/Tnfrsf1atm1Mak Tnip1Gt(E059E05)Wrst/Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6J * NOD)
|
decreased susceptibility to autoimmune diabetes
|
J:64051
|
Tnfrsf1btm1Mwm/Tnfrsf1btm1Mwm
(involves: 129S2/SvPas * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:115225
|
Tnfrsf13btm1Vmd/Tnfrsf13btm1Vmd
(involves: C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:82331
|
increased anti-nuclear antigen antibody level
|
J:82331
|
Tnfsf4tm1Shr/Tnfsf4tm1Shr
(NOD.129S4-Tnfsf4tm1Shr)
|
decreased susceptibility to autoimmune diabetes
|
J:86926
|
Tnfsf10tm1Mjs/Tnfsf10tm1Mjs
(B6.129-Tnfsf10tm1Mjs)
|
increased susceptibility to autoimmune diabetes
|
J:82145
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:101672
|
increased susceptibility to induced arthritis
|
J:82145
|
Tnfsf13tm1Pod/Tnfsf13tm1Pod
(B6.Cg-Tnfsf13tm1Pod)
|
decreased susceptibility to induced arthritis
|
J:141374
|
Tnfsf15tm1Cdon/Tnfsf15tm1Cdon
(B6.129-Tnfsf15tm1Cdon)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:136280
|
Tnfsf15tm1Hluo/Tnfsf15tm1Hluo
(D1LacJ.129(B6)-Tnfsf15tm1Hluo)
|
decreased susceptibility to induced arthritis
|
J:207029
|
Tnip1Gt(E059E05)Wrst/Tnip1Gt(E059E05)Wrst
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:180054
|
increased anti-nuclear antigen antibody level
|
J:180054
|
increased susceptibility to systemic lupus erythematosus
|
J:180054
|
Tnip1m1Btlr/Tnip1m1Btlr
(C57BL/6J-Tnip1m1Btlr)
|
increased anti-double stranded DNA antibody level
|
J:265175
|
Tnip1tm1.1Pcoh/Tnip1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:176826
|
Tnip1tm1.1Pcoh/Tnip1tm1.1Pcoh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:176826
|
increased anti-nuclear antigen antibody level
|
J:176826
|
Tpp2tm1.1Gnie/Tpp2tm1.1Gnie
(involves: 129S6/SvEvTac)
|
increased anti-nuclear antigen antibody level
|
J:221205
|
increased autoantibody level
|
J:221205
|
Tpsab1m1/Tpsab1m1 Tpsb2tm1(cre)Adch/Tpsb2tm1(cre)Adch
(B6.Cg-Tpsb2tm1(cre)Adch Tpsab1m1)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Tpsb2tm1.1Mfg/Tpsb2tm1.1Mfg
(B6.129-Tpsb2tm1.1Mfg)
|
decreased susceptibility to induced arthritis
|
J:142880
|
Traf3tm1Bshp/Traf3tm1Bshp Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * SJL)
|
autoimmune response
|
J:124329
|
increased anti-double stranded DNA antibody level
|
J:124329
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(involves: 129/Sv * BALB/c)
|
increased anti-double stranded DNA antibody level
|
J:93923
|
increased anti-histone antibody level
|
J:93923
|
increased anti-single stranded DNA antibody level
|
J:93923
|
increased autoantibody level
|
J:93923
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(C.129-Traf3ip2tm1.1Lix)
|
increased autoantibody level
|
J:138560
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix
(B6.129-Traf3ip2tm1.1Lix)
|
increased anti-chromatin antibody level
|
J:187766
|
increased anti-double stranded DNA antibody level
|
J:187766
|
increased anti-histone antibody level
|
J:187766
|
increased anti-nuclear antigen antibody level
|
J:187766
|
increased autoantibody level
|
J:187766
|
Traf3ip2tm1.1Lix/Traf3ip2tm1.1Lix Tnfsf13btm1Msc/Tnfsf13btm1Msc
(involves: 129 * 129S2/SvPas * BALB/c)
|
increased autoantibody level
|
J:138560
|
Traf3ip2tm1Sbn/Traf3ip2tm1Sbn
(either: B6.129-Traf3ip2tm1Sbn or (involves: 129) or (involves: 129 * BALB/c))
|
decreased susceptibility to autoimmune disorder
|
J:144320
|
Trem1tm1(KOMP)Vlcg/Trem1tm1(KOMP)Vlcg
(C57BL/6N-Trem1tm1(KOMP)Vlcg/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
Trex1em3Gpt/Trex1em3Gpt
(C57BL/6JGpt-Trex1em3Gpt)
|
increased susceptibility to autoimmune disorder
|
J:330879
|
Trex1tm1.1Fwpe/Trex1tm1.1Fwpe
(involves: 129S1/SvImJ * 129S4/SvJae * 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:220965
|
increased susceptibility to systemic lupus erythematosus
|
J:220965
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd)
|
increased autoantibody level
|
J:202757
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:181257
|
increased susceptibility to systemic lupus erythematosus
|
J:181257
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6N)
|
increased autoantibody level
|
J:234263
|
Trex1tm1Tld/Trex1tm1Tld
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased susceptibility to autoimmune disorder
|
J:243357
|
Trim21tm1Mwah/Trim21tm1Mwah
(C57BL/6-Trim21tm1Mwah)
|
autoimmune response
|
J:151775
|
increased autoantibody level
|
J:151775
|
Trim25tm1Mura/Trim25+ Usp15L749R/Usp15+
(involves: 129S1/SvImJ * 129S4/SvJae * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
Tsc22d3tm1.2Efmd/Y
(Not Specified)
|
abnormal susceptibility to autoimmune disorder
|
J:201728
|
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
increased anti-nuclear antigen antibody level
|
J:119985
|
increased susceptibility to autoimmune disorder
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv)
|
increased susceptibility to autoimmune disorder
|
J:309768
|
Tyk2E775K/Tyk2E775K
(B10.D1-H2q/SgJ)
|
decreased susceptibility to induced arthritis
|
J:69051
|
Tyrobptm1Lll/Tyrobptm1Lll
(involves: 129P2/OlaHsd * C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:64763
|
Tyrobptm1Lll/Tyrobptm1Lll
(involves: 129P2/OlaHsd)
|
decreased susceptibility to induced arthritis
|
J:158811
|
Tyrobptm1Ttk/Tyrobptm1Ttk
(B6.129P2-Tyrobptm1Ttk)
|
increased anti-double stranded DNA antibody level
|
J:177613
|
increased autoantibody level
|
J:177613
|
Ubash3btm1Jni/Ubash3btm1Jni Ubash3atm1Jni/Ubash3atm1Jni
(Not Specified)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:89761
|
Unc93b1tm1.1Kmiy/Unc93b1tm1.1Kmiy
(involves: 129P2/OlaHsd * C57BL/6)
|
increased anti-nuclear antigen antibody level
|
J:174308
|
increased autoantibody level
|
J:174308
|
Usp15L749R/Usp15+
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
Usp15L749R/Usp15L749R
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
Usp15L749R/Usp15tm1Pgrs
(involves: 129S1/SvImJ * C57BL/6J)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
Usp15tm1Pgrs/Usp15tm1Pgrs
(Not Specified)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:259382
|
Usp25Gt(RRS805)Byg/Usp25Gt(RRS805)Byg
(involves: 129P2/OlaHsd)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:188557
|
Vdrtm1Ska/Vdrtm1Ska
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
decreased susceptibility to autoimmune diabetes
|
J:112519
|
Vdrtm1Ska/Vdrtm1Ska
(NOD.Cg-Vdrtm1Ska/CmatJ)
|
increased susceptibility to autoimmune diabetes
|
J:127787
|
Vsig4tm1Gne/Vsig4tm1Gne
(C57BL/6-Vsig4tm1Gne)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:281762
|
Vsirtm1Lex/Vsirtm1Lex Tg(Tcra2D2,Tcrb2D2)1Kuch/0
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:222944
|
Vtcn1tm1Xxz/Vtcn1tm1Xxz
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased susceptibility to autoimmune diabetes
|
J:177612
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:177612
|
Vwftm1Wgr/Vwftm1Wgr
(B6.129S2-Vwftm1Wgr)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:140334
|
Wastm1Itl/Y
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Itl/Wastm1Itl
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Y
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Y
(involves: 129S6/SvEvTac * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
Wastm1Sbs/Wastm1Sbs
(involves: 129S6/SvEvTac)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm1Sbs/Wastm1Sbs
(involves: 129S6/SvEvTac * C57BL/6)
|
increased anti-chromatin antibody level
|
J:182528
|
increased anti-double stranded DNA antibody level
|
J:182528
|
increased anti-single stranded DNA antibody level
|
J:182528
|
increased autoantibody level
|
J:182528
|
Wastm2Itl/Y
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wastm2Itl/Wastm2Itl
(Not Specified)
|
increased anti-double stranded DNA antibody level
|
J:153247
|
Wipf1tm1Geha/Wipf1tm1Geha
(involves: 129S6/SvEvTac * C57BL/6)
|
increased autoantibody level
|
J:116168
|
Xcl1tm1.1Dnax/Xcl1tm1.1Dnax
(either: (involves: 129/Sv * BALB/c) or (involves: 129/Sv * C57BL/6))
|
autoimmune response
|
J:176844
|
Xkrxtm1b(EUCOMM)Wtsi/Xkrxtm1b(EUCOMM)Wtsi
(C57BL/6N-Xkrxtm1b(EUCOMM)Wtsi/Wtsi)
|
increased anti-nuclear antigen antibody level
|
J:211773
|
X/Yaa
((NZB x BXSB)F1)
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:6235
|
increased autoantibody level
|
J:6235
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
((SJL/J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
((C57BL/6J x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
(involves: BXSB * NZB)
|
increased susceptibility to autoimmune disorder
|
J:6235
|
X/Yaa
(BXSB/MpJ)
|
increased anti-erythrocyte antigen antibody level
|
J:6235
|
increased anti-nuclear antigen antibody level
|
J:179430
|
increased susceptibility to autoimmune disorder
|
J:108760,
J:6235
|
X/Yaa
((NZW x SB)F1)
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/Yaa
((NZW x BXSB)F1)
|
increased susceptibility to autoimmune disorder
|
J:7276
|
X/Yaa
(BXSB/MpJScr)
|
increased anti-nuclear antigen antibody level
|
J:10973
|
increased susceptibility to autoimmune disorder
|
J:10973
|
YaailNZW/Ola/?
(involves: C57BL/6Ola * NZW/Ola)
|
increased anti-double stranded DNA antibody level
|
J:52110
|
Zap70m1Saka/Zap70m1Saka
(involves: BALB/c)
|
increased autoantibody level
|
J:86607
|
increased susceptibility to induced arthritis
|
J:154166
|
rheumatoid arthritis
|
J:86607
|
Zap70m1Saka/Zap70tm2.1Weis
(involves: 129S4/SvJae * BALB/c)
|
decreased susceptibility to induced arthritis
|
J:154166
|
Zc3h12atm1Aki/Zc3h12atm1Aki
(involves: 129X1/SvJ * C57BL/6)
|
increased anti-double stranded DNA antibody level
|
J:147868
|
increased anti-nuclear antigen antibody level
|
J:147868
|
Zc3h12atm1c(EUCOMM)Hmgu/Zc3h12atm1c(EUCOMM)Hmgu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * C57BL/6N * DBA)
|
increased anti-nuclear antigen antibody level
|
J:304105
|
increased autoantibody level
|
J:304105
|
Zc3h12dtm1Tom/Zc3h12dtm1Tom
(B6.Cg-Zc3h12dtm1Tom)
|
increased susceptibility to experimental autoimmune encephalomyelitis
|
J:209383
|
Zfp36tm2.1Pjb/Zfp36tm2.1Pjb
(involves: C57BL/6)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:229078
|
decreased susceptibility to induced arthritis
|
J:229078
|
Zranb1tm1c(EUCOMM)Hmgu/Zranb1tm1c(EUCOMM)Hmgu Tg(Itgax-cre)1-1Reiz/0
(involves: 129S4/SvJaeSor * C57BL/6N * CBA)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|
Zranb1tm1d(EUCOMM)Hmgu/Zranb1tm1d(EUCOMM)Hmgu
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6N)
|
decreased susceptibility to experimental autoimmune encephalomyelitis
|
J:235701
|